



LUND UNIVERSITY

Bactericidal/Permeability-Increasing Protein (BPI) and Proteinase 3: Studies at the Transcriptional Level

Pieters, Katrien

2005

[Link to publication](#)

Citation for published version (APA):

Pieters, K. (2005). *Bactericidal/Permeability-Increasing Protein (BPI) and Proteinase 3: Studies at the Transcriptional Level*. [Doctoral Thesis (compilation), Division of Hematology and Clinical Immunology]. Division of Hematology and Transfusion Medicine, Lund University.

Total number of authors:

1

General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

Bactericidal/Permeability-Increasing Protein (BPI) and Proteinase 3: Studies at the Transcriptional Level

Doctoral Thesis

Katrien Pieters

Division of Hematology and Transfusion Medicine
Lund University 2005
Sweden

With the approval of the Faculty of Medicine, Lund University, to be presented
for public examination at the BioMedical Center (BMC), Segerfalksalen,
June 9, 2005, at 9:15.

Faculty opponent
Professor Lars Hellman
Institution for Cell-and Molecular Biology
Uppsala University
Sweden

Division Of Hematology
and Transfusion Medicine
Lund University
Sweden

Copyright © Katrien Pieters, 2005
ISBN 91-85439-58-4
Printed By Media-Tryck
Lund 2005

Kunskap

*Vad gjorde oss mänskliga?
Inte alltid kärleken.
Mycket sällan njutningen.
Kanske oftare lidandet.
Måhända intelligensen?
Jo, allra mänskligast
var vår iver att avnjuta
intellektets smak för
negationens bittra sötma.
Förkasta för en upptäckt.
Åh, den där ambitionen
att skapa en ny värld –
som om vi känt en gammal.
Så kom vi då fram en bit
på vägen, ängsliga, gamla,
men likt yrvakna skolbarn,
välkammade, vi bar namn-
brickor, små tygväskor,
i dem förvarade vi våra
hemliga anteckningar
om livets mening.*

Jacques Werup

*Ur Hundra Dikter från fyra
decemier.*

Abstract

In myelopoiesis, neutrophils and monocytes/macrophages are formed from a common myeloid precursor cell in the bone marrow. During maturation of neutrophils, cytoplasmic granules are formed in the cells and the content of these granules is critical for the function of neutrophils in the first line of defense against invading microorganisms. The Bactericidal/Permeability-Increasing protein (BPI) is stored in azurophil granules of the neutrophil and is cytotoxic against gram-negative bacteria. Absence of BPI in neutrophils of patients with Specific Granule Deficiency (SGD) and late expression of BPI at the promyelocyte stage, suggest a different regulation at the transcriptional level as compared to other azurophil granule proteins. In this thesis, we show that the transcription factors AML-1, PU.1, and Sp3 regulate the expression of human BPI in myeloid cells. We also identified a mouse ortholog to human BPI, expressed in bone marrow, testis and epididymis. However, the expression of BPI in mouse bone marrow cells is much lower than that in human bone marrow cells, indicating important differences in the transcriptional regulation. We suggest that, in contrast to human BPI, lack of C/EBP binding sites is responsible for the low expression of BPI in mouse bone marrow cells.

The expression of another azurophil granule protein, human proteinase 3, is shown to be increased in myeloid cells of patients with Wegener's Granulomatosis (WG). This increased expression of proteinase 3 might be a risk factor for the development of the disease. We show that the overrepresented -564 A/G SNP in WG patients, which introduces a new potential Sp1 transcription factor binding site, is not the reason for increased proteinase 3 expression in these patients.

Original papers

This thesis is based on the following papers, which are referred to in the text by their respective roman numerals.

- I. Lennartsson A., Pieters K., Ullmark T., Vidovic K, and Gullberg U. (2003) AML-1, PU.1, and Sp3 regulate expression of human bactericidal/permeability-increasing protein. *Biochemical and Biophysical Research Communications*, 311: 853-863.
- II. Lennartsson A., Pieters K., Vidovic K., and Gullberg U. (2005) A murine antibacterial ortholog to human bactericidal/permeability-increasing protein (BPI) is expressed in testis, epididymis, and bone marrow. *Journal of Leukocyte Biology*, 77: 369-377.
- III. Pieters K, Lennartsson A, Gullberg U. Cloning and characterization of the mouse bactericidal/permeability-increasing protein (BPI) gene promoter. Manuscript.
- IV. Pieters K., Pettersson Å., Gullberg U., and Hellmark T. (2004) The -564 A/G polymorphism in the promoter region of the proteinase 3 gene associated with Wegener's granulomatosis does not increase the promoter activity. *Clinical and Experimental Immunology*, 138: 266-270.

Contents

| | |
|--|-----------|
| I. Background | 1 |
| A. Haematopoiesis, general features | 1 |
| B. Myelopoiesis | 3 |
| <i>B.1. The role of transcription factors in myelopoiesis</i> | 5 |
| <i>B.1.1. Transcription factors and lineage choice</i> | 5 |
| <i>B.1.2. Transcription factors and receptor-mediated signals</i> | 7 |
| <i>B.1.3. Transcription factors and disease</i> | 7 |
| <i>B.1.4. Transcription factors and neutrophil granule protein expression</i> | 9 |
| <i>B.1.5. Summary of transcription factors and neutropoiesis</i> | 11 |
| <i>PU.1</i> | 13 |
| <i>C/EBPs</i> | 14 |
| <i>AML-1</i> | 15 |
| <i>Sp1/Sp3</i> | 15 |
| <i>CDP</i> | 17 |
| C. General aspects of transcriptional regulation | 19 |
| <i>C.1. The core promoter</i> | 19 |
| <i>C.2. Regulatory transcription factors</i> | 20 |
| <i>C.3. The activation or repression of a gene</i> | 21 |
| D. Proteins and peptides and their role in innate immunity | 22 |
| <i>D.1. The migration of mature leukocytes to sites of infection</i> | 22 |
| <i>D.2. Antimicrobial proteins and peptides in phagocytic and non-phagocytic cells</i> | 23 |
| <i>D.3. Human BPI</i> | 25 |
| <i>D.4. Similarities and differences between LPS-binding protein and BPI</i> | 26 |
| <i>D.5. BPI and its relatives</i> | 28 |
| <i>D.6. Proteinase 3 and its role in Wegener's Granulomatosis (WG)</i> | 29 |

| | |
|---|-----------|
| II. Aims of the present studies | 32 |
| III. Experimental considerations | 33 |
| A. Determination of the transcription start site | 33 |
| B. Measurement of transcriptional activity | 34 |
| C. Determination of the functional importance of transcription factors | 38 |
| <i>C. 1. Deletion analysis</i> | 38 |
| <i>C. 2. Computer-based search for potential cis-elements</i> | 39 |
| <i>C. 3. Site-directed mutagenesis</i> | 39 |
| <i>C. 4. EMSA</i> | 40 |
| <i>C. 5. ChIP</i> | 41 |
| <i>C. 6. Overexpression of recombinant transcription factor</i> | 42 |
| IV. Results and general discussion | 43 |
| A. The BPI promoters | 43 |
| <i>A.1. Are the promoters of the human- and mouse BPI genes comparable? (Paper I, II, and III)</i> | 43 |
| <i>A.2. Is the transcriptional regulation of the BPI genes comparable to other neutrophil granule protein genes? (Paper I, II, and III)</i> | 48 |
| B. A mouse antibacterial ortholog to human BPI (Paper II) | 51 |
| C. The Single Nucleotide Polymorphism (SNP) in the proteinase 3 promoter (Paper IV) | 54 |
| V. Conclusions | 56 |
| Populärvetenskaplig sammanfattning på Svenska (Samenvatting in het Zweeds) | 58 |
| Samenvatting in het Vlaams (Populärvetenskaplig sammanfattning på Flamländska) | 60 |
| Acknowledgements | 63 |
| References | 66 |
| Appendix papers I-IV | 90 |

Selected abbreviations

| | |
|--------------------------------|--|
| AASV | ANCA-associated small vessel vasculitis |
| AML | acute myeloid leukemia |
| ANCA | anti-neutrophil cytoplasmic autoantibodies |
| APL | acute promyelocytic leukemia |
| ATRA | all- <i>trans</i> -retinoic acid |
| BPI | bactericidal/permeability-increasing protein |
| C/EBP | CCAAT/enhancer binding protein |
| CD | cluster of differentiation |
| CDP | CCAAT displacement protein |
| G-CSF | granulocyte-colony stimulating factor |
| GM-CSF | granulocyte-monocyte-colony stimulating factor |
| GTF | general transcription factor |
| HAT | histone acetyl transferase |
| HDAC | histone deacetylase |
| IL | interleukin |
| LBP | LPS-binding protein |
| LPS | lipopolysaccharide |
| M-CSF | monocyte-colony stimulating factor |
| MPO | myeloperoxidase |
| NE | neutrophil elastase |
| PLUNC | palate, lung and nasal epithelial clone |
| PMN | polymorphonuclear neutrophil |
| PR3 | proteinase 3 |
| RARα | retinoic acid receptor-alpha |
| RARE | retinoic acid response element |
| RTF | regulatory transcription factor |
| SGD | specific granule deficiency |
| TBP | TATA-binding protein |
| TLR | toll-like receptor |
| TNF-α | tumor necrosis factor-alpha |
| WG | wegener's granulomatosis |

I. Background

A. Haematopoiesis, general features

Haematopoiesis means formation of blood cells and is a process which occurs in the bone marrow. A rare population (<0,1%) of pluripotent stem cells have the ability to self-renew as well as to differentiate to committed multipotential haematopoietic precursor cells. The human haematopoietic system has an enormous amplification rate: one stem cell is capable of producing about 1 million mature blood cells after 20 cell divisions and this production continues during human lifetime.

The committed multipotential precursor cells are highly proliferative cells that express receptors for specific growth-and survival factors, like colony-stimulating factors (CSF's), and after differentiation finally form seven distinct classes of mature blood cells, including erythrocytes, B cells, T cells, NK cells, granulocytes, monocytes/macrophages, and megakaryocytes. When released from the bone marrow into the blood circulation, each of these mature cell types possess unique properties and perform specific distinct functions. Erythrocytes or red cells function during 120 days in the blood circulation where they transport oxygen (O₂) from the lungs to the tissues where it is exchanged for carbon dioxide (CO₂). The platelets, formed from megakaryocytes, make mechanical plugs during the normal haemostatic response to vascular injury. B cells, T cells, NK cells, granulocytes, and monocytes /macrophages belong to a group of leukocytes which are central to all immune responses in our body. Neutrophils, which together with the eosinophils and basophils, belong to the class of granulocytes, are the most important cells in the first line of defense against invading microorganisms in our tissues, a defense system also called innate immunity. Monocytes/macrophages and neutrophils perform phagocytic functions, which means that they during infection or inflammation migrate into infected or inflamed tissues, bind to the microorganisms, internalize them and then destroy them. Other leukocytes, like B cells and T cells are responsible for the adaptive immune responses and fall into another category of cells, the so called lymphocytes. When B cells have recognized its specific antigen, they divide

and differentiate into plasma cells which produce antibodies specific against the recognized antigens. These plasma cells are memory cells that confer a long-term immunity against the recognized antigens. A second group of lymphocytes are the T cells, which in their turn are subdivided in different types of T cells. T cells express T-cell Receptors (TCR) on their surface for the recognition of specific antigens presented by MHC molecules on the surface of other cells, the so called antigen-presenting cells (APC). One type of T cell is called T-helper cell and can interact with B cells and helps them to divide, differentiate and to produce antibodies. T-helper cells can also interact with macrophages helping them with destroying the ingested pathogens. T-cytotoxic cells are a second type of T cells and interact with host cells infected with virus and other microorganisms and finally destroy these cells. Natural Killer (NK) cells, which are a type of large granular lymphocyte, can destroy infected host cells which lack of have lost their MHC molecules and in this way belongs to the innate immunity [1-3].




Figure 1. The differentiation towards neutrophils and monocytes/macrophages is called myelopoiesis.

B. Myelopoiesis

Neutrophils and monocytes/macrophages all derive from a common myeloid precursor cell and their differentiation process is called myelopoiesis (as illustrated in **figure 1**). During myelopoiesis, cytoplasmic granules of the neutrophil are formed. Cytoplasmic granules are characteristic for these cells and the content of the granules is necessary for the cells to be functionally active. In humans, differentiation of the myeloid cells takes place in the bone marrow over a period of 10 to 14 days, followed by the release of the mature myeloid cells into the peripheral blood [4].

The mature blood neutrophil, also called polymorphonuclear neutrophil (because of its segmented nucleus), contains many types of granules and these are formed at different stages during the myelopoiesis, including the myeloblast stage, promyelocyte, myelocyte, metamyelocyte, band cell, and finally the mature polymorphonuclear neutrophil.

The earliest appearing granules are formed during the promyelocyte stage and are named azurophil (primary) granules followed in time by the specific (secondary), gelatinase (tertiary) granules, and finally the secretory vesicles [5]. The classical distinction between the early-appearing granules (primary) and the later-appearing granules (secondary, tertiary) is based on the fact that primary granules contain the protein myeloperoxidase (MPO), while the other granules not [6]. Further investigations of the structure and protein content of the granules revealed two heterogeneous populations of granules rather than two well-defined granule types [7-10]. The azurophil (primary) granules are further divided in several subpopulations based on heterogeneity in size, shape and protein content [4, 7, 10], but also on differences in time of appearance during the early stage of myelopoiesis. Based on this, azurophil granules can be divided in two major subgroups: early-appearing defensin-poor granules, which are formed at the beginning of the promyelocyte stage, and late-appearing defensin-rich granules, formed at the transition of promyelocyte and myelocyte stage [11]. Alpha-defensins form together with myeloperoxidase (MPO) major constituents in azurophil granules, but also proteins like bactericidal/permeability-increasing protein (BPI) and the closely related serine protease homologues neutrophil elastase (NE), proteinase 3 (or myeloblastin),

azurocidin, and cathepsin G are found in these granules. The secondary (specific) and tertiary granules, which do not contain myeloperoxidase (MPO), can be divided into three subgroups based on the content of lactoferrin and gelatinase: 15% of these granules contain lactoferrin but no gelatinase; 60% contain lactoferrin and gelatinase and 25% contain gelatinase but no lactoferrin [9]. The expression of these peroxidase-negative granules occurs as a continuum in myelocytes, metamyelocytes, band cells and segmented neutrophils and besides lactoferrin and gelatinase, they also contain the peptide hCAP-18, lipocalin, lysozyme (which is found in all granule types) and collagenase.

This granule heterogeneity separates proteins that cannot co-exist in the same granule [12] and is explained by differences in timing of gene expression. Arnljots and co-workers found that major differences exist in timing of biosynthesis of MPO, defensins and lactoferrin in relation to maturation of myeloid cells and that this can explain the differences in subcellular localization of the individual granule proteins [11].

The gene expression of the individual granule proteins during myelopoiesis is regulated at different levels and one of the main regulatory mechanisms is at the level of access to the DNA sequences, that is, at the chromatin level. Genes or DNA sequences are very tightly assembled into chromatin, which make them transcriptionally inactive. The conformational changes of chromatin, also called remodeling of chromatin, makes genes accessible to bind DNA-binding proteins (transcription factors). The initiation or start of transcription is 'primary' regulated by the interplay of molecular interactions between transcription factors and promoter and/or enhancer sequences. At this level of transcription, DNA is converted into primary RNA transcript which undergoes post-transcriptional modifications to form a mature mRNA (messenger RNA). This mRNA is then transported from the nucleus to the cytoplasm, where it is translated into protein which is subjected to different types of post-translational events. Lots of studies have been done on post-translational mechanisms, like processing and targeting of the granule proteins in neutrophils [13], as well as studies on regulation of gene expression at the transcriptional level [14, 15].

In this thesis, I have focused on the transcriptional regulation of the gene expression of Bactericidal/Permeability-Increasing protein (BPI) and proteinase 3. Human BPI and proteinase 3 are stored in the azurophil granules of the neutrophil granulocyte, but human BPI is also found in some epithelial tissues. We also cloned and identified a mouse ortholog to human BPI which was found to be expressed in bone marrow cells, but also in testis-and epididymis tissue. A study of the promoter structure of this 'novel' mouse BPI was initiated and some interesting, although preliminary, differences between the transcriptional regulation of human and mouse BPI were found. All three proteins, human BPI, human proteinase 3, and probably also mouse BPI play specific roles in innate immunity and this will be described in more detail later in this thesis.

B. 1. The role of transcription factors in myelopoiesis

Lots of studies have been made to understand how myeloid precursor cells undergo commitment and become mature neutrophil granulocytes or monocytes/macrophages. The action of transcription factors in response to specific growth factors or interleukins play a major role in both commitment and maturation of myeloid cells. Transcription factors can act both positively and negatively to regulate the expression of genes encoding for typical granule proteins, but also expression of specific growth factors and their receptors and expression of other transcription factors.

B. 1. 1. Transcription factors and lineage choice

PU.1 is one of the crucial transcription factors identified to regulate the differentiation of myeloid cells. PU.1 seems to be required for the development of the early multipotential myeloid precursor cells [16, 17] and plays also an essential role in the development of monocytes/macrophages later during myelopoiesis [18, 19]. The precise mechanisms of the differentiation from the committed multipotential myeloid precursor cell into either neutrophils or monocytes/macrophages is still not fully understood. One hypothesis [20] is that the continued expression of PU.1 leads to the development of the 'default'

pathway, this means the differentiation of the myeloid progenitor cells into monocytes/macrophages. According to this model (see schematic representation in **figure 2**), C/EBP α , another important transcription factor during myelopoiesis, can inhibit the function of PU.1 and up-regulation of the activity of C/EBP α results in induction of the granulocytic development and inhibition of monocytic development [21, 22].

PU.1 regulates almost all the myeloid genes including the receptors for granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF) and granulocyte colony-stimulating factor (G-CSF) [19, 23-25]. The differentiation into monocytes/macrophages is dependent on the expression of the receptor for M-CSF and the monocyte/macrophage differentiation process can only take place efficiently if the cells respond to this specific growth factor [18]. PU.1 deficient cells can commit into the granulocytic and monocytic lineages, but cannot fully support maturing along these lineages [26-28]. C/EBP α deficient mice fail to undergo myeloid differentiation beyond the myeloblast stage and therefore lack mature neutrophils, but show no lack of mature monocytes [29]. In contrast to PU.1, loss of C/EBP α affects the expression of the G-CSF receptor, but not the receptors for GM-CSF or M-CSF [25].




Figure 2. Schematic representation of myeloid lineage choice. Modified from Tenen, 1997.

B. 1. 2. Transcription factors and receptor-mediated signals

The activity of several transcription factors during myelopoiesis is controlled by external stimuli, such as cytokines and specific growth factors. Activation of transcription factors, such as PU.1 and C/EBP α , induces expression of specific cytokine receptors (**Figure 2**). One of these, the granulocyte colony stimulating factor (G-CSF) receptor regulates the production of granulocytes [30]. Signals from this G-CSF receptor activate c-Jun, the co-activator of PU.1, and both proteins bind to the promoters of several myeloid genes resulting in the induction of differentiation of myeloid cells [31, 32].

According to one model, transcription factors rather than cytokine receptor signals are key regulators in myelopoiesis [33]. This hypothesis is based on some data in the literature including the observation that mice lacking G-CSF, the G-CSF receptor, or G-CSF and GM-CSF, have a reduction in granulocyte production, indicating their importance for myelopoiesis [30]. However when compared to mice lacking the transcription factors PU.1 or C/EBP α , the impairment in granulocyte production was much greater in the latter case [17, 29, 34], demonstrating the critical importance of transcription factors. Furthermore, the introduction of the G-CSF receptor into PU.1 deficient bone marrow cells failed to restore terminal myeloid differentiation [35].

Myeloid differentiation can also be induced by the Retinoic Acid Receptor-alpha (RAR α) which function both as a transcription factor and a nuclear receptor able to bind retinoic acid (RA), a small lipophilic molecule that is derived from retinol, or vitamin A [36-38]. A dominant-inhibition of RAR α arrests myelocytic differentiation at the promyelocyte stage [39], while treatment of the leukemic NB4 cells by all-trans retinoic acid (ATRA) induced the granulocytic differentiation of these cells and the induction of C/EBP ϵ transcript, which is a direct target gene of RAR α [40-43].

B. 1. 3. Transcription factors and disease

The hypothesis [20, 33], as mentioned above, that transcription factors, and not the external growth factors and cytokines are the critical decision points for myeloid differentiation is supported by the fact that many genes which are

involved in chromosomal translocations or mutations in acute myeloid leukemia (AML) are transcription factors [20, 33].

Acute myeloid leukemia (AML) is a disease which is characterized by accumulation of immature myeloid cells blocked in their differentiation program.

The transcription factor AML-1 (or CBF α 2), which acts earlier than PU.1 during haematopoiesis, is found to be essential for the expression of some myeloid-specific genes, including M-CSF, GM-CSF, and myeloperoxidase (MPO) [19, 44, 45]. The AML1 gene is located at the translocation breakpoint on chromosome 21 in the t(8; 21) translocation and forms the fusion gene AML1/ETO, which encodes the most common fusion protein found in AML patients [46]. The fusion protein consists of the N-terminal part of AML1 fused to almost the complete ETO protein [47] and represses genes that are normally activated by wild type AML1 [44]. Further, the AML1/ETO fusion protein disrupts C/EBP α function [48] and might also inhibit PU.1 function [49]. Some AML patients which do not have this common translocation t(8; 21) are found to have mutations either in the PU.1 gene [50] or in the C/EBP α gene [51]. The mutations in the C/EBP α gene are divided into two common types: mutations in the C-terminus which disrupts the DNA binding as well as homo- and heterodimerization with other C/EBP family members, and N-terminal frameshift mutations resulting in a truncated protein [51]. The truncated protein is also inhibited in its DNA-binding ability [24, 51].

Acute Promyelocytic Leukemia (APL), a subtype of AML, which is characterized by a block in differentiation at the promyelocyte stage, is known to be associated with at least five types of reciprocal chromosomal translocations. These translocations always involve the retinoic acid receptor-alpha (RAR α) on chromosome 17. The majority of APL patients carry the chromosomal translocation t(15; 17) that fuses RAR α to the promyelocytic gene PML [52-54]. The fusion genes encoding PML/RAR α protein are known to inhibit the expression of C/EBP ϵ , a transcription factor important in the terminal stages of neutrophil maturation [55] and may also inhibit C/EBP α activity [56]. APL patients which carry the PML/RAR α fusion protein in their

cells respond to retinoic acid RA-induced differentiation therapy [57]. This in contrast to another type of APL patients which carry the PLZF/RAR α fusion protein in their cells, these patients are not affected by therapy with ATRA as a result of its stronger association with the co-repressor proteins SMRT, mSIN3 and Histone Deacetylase-1 (HDAC) [58]. APL cells with PLZF/RAR α protein may, however, respond to ATRA by cotreatment with histone deacetylase (HDAC) inhibitors [59].

A very rare congenital disorder, not related to acute myeloid leukemia (AML), is the neutrophil Specific granule Deficiency (SGD) [60, 61]. SGD is another example that supports the hypothesis that transcription factors are critical for the differentiation of myeloid cells. The neutrophils of SGD patients are blocked at the promyelocyte to myelocyte stage in their differentiation program caused by homozygous mutations of the C/EBP ϵ gene. There are, however, only five SGD patients reported worldwide and only 2 of them show structural abnormalities in the C/EBP ϵ gene, which probably means that the molecular basis of SGD may involve other factors as well [61, 62].

B. 1. 4. Transcription factors and neutrophil granule protein expression

A characteristic of normal neutrophil maturation is the induction of granule protein expression. Potential binding sites for a variety of transcription factors have been identified in the promoter –and/or enhancer regions of several neutrophil granule proteins.

In human, the gene encoding the early-appearing granule protein myeloperoxidase (MPO) contains a functional Sp1 site in the 139 bp minimal promoter [63] and has a distal enhancer with a functional binding site for AML1 [64]. The mouse and human MPO promoters are in close homology [65, 66], lack both a TATA-box, but transcription of the human gene is initiated near a CATAA element adjacent to the first exon [67, 68]. The distal enhancer of human MPO, which shows a functional binding site for AML1, is located 1 kb upstream from the transcription start site and shows close homology with the mouse MPO enhancer [69]. The mouse MPO enhancer is also activated by PU.1 and C/EBP α [25, 70, 71] and c-myb cooperates with PEBP2/CBF

(murine homolog to human AML1) to regulate this enhancer activity [45, 72]. The genes of proteinase 3, elastase and azurocidin, three members of the serine protease family, are clustered within 50 kb on the human chromosome 19 [73]. The promoter activity of the proteinase 3 (PR3) gene is dependent of a functional PU.1 site and a potential CG-site within the first 200 bp upstream of the transcription start. This promoter region also contains a potential TATA-box [74] and a functional C/EBP - and c-myb site [75, 76]. Studies in mouse 32Dcl3 myeloid cells revealed an enhancer located in the second intron of the proteinase 3 gene which bound Sp1 and an ets factor [77]. All the azurophil granule serine proteinase promoters contain a TATA-box [73, 78, 79]. Cis-elements found to be functional in the mouse elastase promoter include PU.1, C/EBP α and c-myb [80]. Alignment of the first 120 bp of the mouse proteinase 3 and mouse elastase promoters shows conservation of the position of the binding sites for c-myb, PU.1 and TATA-box [81].

The alpha-defensins (HNP1 and HNP3) have promoters that contain potential binding sites for c-myb, AML1, ets family members, and CDP/cut (CCAAT displacement protein) [82]. CDP is known as a repressor of transcription at the myeloblast and promyelocyte stage and its activity as repressor is down-regulated upon differentiation of myeloid cells [83-85]. However, the functional significance of this CDP-site in the HNP1 and HNP3 promoters is not yet demonstrated.

The gene expression of human lactoferrin, a secondary granule protein, is also repressed by CDP/cut (CCAAT displacement protein). Maturation past the promyelocytic stage results in decreased binding of CDP/cut to the silencer element, leading to high levels of lactoferrin mRNA expression [86]. Another transcription factor which binds to the lactoferrin promoter upon induction of maturation is C/EBP ϵ , a transcription factor known to be critical in the terminal steps of neutrophil differentiation [87]. Uninduced human leukemic NB4 cells which do not lack C/EBP ϵ , lack lactoferrin because of persistent binding of CDP/cut to the silencer element in the lactoferrin promoter [86]. There are many sequence similarities between human and mouse lactoferrin promoters including functional binding sites for Sp1 [88, 89] and C/EBP ϵ [90]. A study done with nuclear extracts derived from the human monoblastic cell line U937

revealed a functional binding of C/EBP α and Sp1 to the lactoferrin promoter and it is hypothesized that both factors interact with each other to positively regulate the expression of the endogenous gene [91].

In a very recent report, C/EBP α is bound to C/EBP sites in the promoters of human lactoferrin and human collagenase in uninduced MPRO cells, which do not express the mRNAs of both secondary granule proteins, C/EBP α probably binds to an heterodimeric partner to negatively regulate these late-appearing granule proteins. In ATRA-induced MPRO cells, there is a change in the dynamics of C/EBP binding, probably resulting in C/EBP α : ϵ heterodimer formation, which correlates with the induced expression of the lactoferrin and collagenase genes [92]. Here, it should be remembered that all the studies are done in the mouse MPRO cell line and that regulation may be different in the human context.

The important role of C/EBP ϵ in the regulation of the secondary and tertiary granule gene expression is based on several studies, including studies with C/EBP ϵ -deficient mice. The granulocytes of C/EBP ϵ -deficient mice show a block in differentiation at the promyelocyte-myelocyte stage and as a consequence these granulocytes lack secondary and tertiary granule proteins, such as lactoferrin and collagenase. Screening of the human leukemic cell lines, HL60, NB4 and U937, which are blocked in differentiation at the promyelocyte stage, showed no expression of the secondary granule proteins such as lactoferrin and collagenase [93, 94]. The ectopic overexpression of C/EBP ϵ in U937 cells can induce the transcription of these secondary granule proteins, such as lactoferrin, and induces in parallel the differentiation of these cells [43].

B. 1. 5. Summary of transcription factors and neutropoiesis

Neutrophils and monocytes/macrophages develop from a common multipotential myeloid precursor stem cell and have some common transcription factors necessary for their differentiation. During neutropoiesis (granulopoiesis), PU.1, C/EBP α , RAR α , AML-1 and c-myb are critical for the expression of the early-appearing azurophil granule proteins, while C/EBP ϵ

plays a role in the expression of the late-appearing secondary and tertiary granule proteins. The expression of the secondary granule protein lactoferrin and the tertiary granule protein gelatinase is repressed by CDP. In **figure 3**, I present a partly hypothetical distribution scheme of neutrophil transcription factors and granule proteins during neutrophil differentiation in human bone marrow, as modified from [95, 96].




Figure 3. A partly hypothetical distribution scheme of neutrophil transcription factors and granule proteins during neutrophil differentiation in human bone marrow, as modified from Borregaard N. (2001) and Bjerregaard MD. (2003). MB: myeloblasts; PM: promyelocytes; MC: myelocytes; MM: metamyelocytes; BC: band cells; PMN: polymorphonuclear neutrophils.

What will follow is a description of protein structure, expression pattern, protein-protein interactions (cooperativity and synergy with other factors) and post-translational modifications of some transcription factors critical for myelopoiesis. Summary is given in **Table 1**.

PU.1

PU.1 is a member of the Ets family of transcription factors and binds DNA as a monomer via its C-terminal Ets domain to the consensus site 5'-AAAG(A/C/G)GGAAG-3'[97]. High levels of both PU.1 mRNA and DNA binding activity have been found in B cells, monocytes and granulocytes and the ability of PU.1 to activate its own promoter provides an explanation why there are such high expression levels of PU.1 in myeloid cells [98]. A co-activator of PU.1, called c-JUN, is required to differentiate myeloid cells towards monocytes [32] and c-JUN levels increase during monocytic differentiation [99]. C/EBP α down-regulates c-JUN and this mechanism is critical for the differentiation of myeloid cells towards granulocytes [100]. PU.1 also interacts with GATA-1, another transcription factor [101, 102], and inhibits the ability of GATA-1 to activate erythroid genes, thereby contributing to the expression of myeloid-specific genes [103, 104]. PU.1 has been shown to functionally interfere with the Retinoic Acid Receptor (RAR α) and this interaction can inhibit PU.1 transactivation function, but the functional significance with respect to myeloid development of this latter interaction is not known [105]. Interferon Consensus Sequence Binding Protein (ICSBP) can interact with PU.1 in monocytic cells, enabling trans-activation via a hybrid DNA-binding element [106, 107]. Beside the physical interactions with c-JUN, GATA-1, RAR α and ICSBP, the transactivating potential of PU.1 can be modulated by phosphorylation [108]. MAP kinase and JUN kinase can phosphorylate PU.1 [109] with phosphorylation of serines 41 and 45, possibly regulating PU.1 activity in myeloid cells [110].

CCAAT/Enhancer Binding Proteins (C/EBPs)

This family of transcription factors includes C/EBP α , β , γ , δ , ϵ and CHOP, which are all strongly similar in their C-terminal dimerization (leucine-zipper) domains and DNA-binding (basic-region) domains, but differ in their N-terminal transactivation domains, with the exception of CHOP, which lacks this transactivation domain completely [111-113]. C/EBP α is the founding member of this family and was the first protein noted to have the leucine zipper domain [114]. Because of the high conservation of the leucine zipper domain, the different C/EBP proteins are able to form homodimers with themselves or heterodimers with all the other intrafamilial proteins [115]. Both the leucine zipper dimerization motif and the basic DNA-binding motif assume an α -helical configuration and dimerization is a prerequisite for DNA binding [116-118]. C/EBP γ and CHOP lack the N-terminal transactivation domain and therefore act as inhibitors of transcription by forming inactive heterodimers with other C/EBP members [119, 120]. The C/EBP proteins cannot only form protein-protein interactions with other leucine zipper proteins, but can also bind transcription factors which do not possess this domain [121], including NF- κ B, Rel-proteins [122, 123] and Sp1 [124].

By use of alternative translation initiation codons, C/EBP α and C/EBP β can produce different sized polypeptides, also called isoforms. C/EBP α is present in isoforms 42 kDa and 30 kDa and the isoform of 30 kDa shows lower activation potential than the 42 kDa form [125]. C/EBP β produces at least 3 isoforms: 38 kDa, 35 kDa and 20 kDa [126].

A combination of differential splicing and alternative use of two different promoters in the gene of C/EBP ϵ gives four different mRNA isoforms, which in turn are translated into four different-sized C/EBP ϵ proteins: 32 kDa, 30 kDa, 27 kDa and 14 kDa. Full-length protein of 32 kD possesses the greatest transactivating potential, while the 14 kDa protein lacks the transactivation domain and can inhibit the activity of the other isoforms [41]. Detailed information about the expression of C/EBP ϵ isoforms during myeloid differentiation is still unknown, but studies have shown that the two isoforms of

32-and 30 kDa can directly bind with the DNA binding domain of c-myb and cooperatively activates the transcription of myeloid promoters [127].

The C/EBP proteins are expressed in a number of tissues, but their expression in the haematopoietic system may be limited to myeloid cells [128], with the exception of C/EBP ϵ expression which is expressed also in lymphoid cells [55, 129, 130]. C/EBP α is besides myeloid cells, expressed at high levels in the adipose tissue, liver, intestine, lung, adrenal gland, peripheral-blood mononuclear cells and placenta [111, 131].

AML-1

This transcription factor is a member of the core binding factor (CBF) -family. CBF proteins are heterodimers composed of an α -subunit (CBF α 1; CBF α 2 or AML-1; CBF α 3) and the β -subunit (CBF β) [132]. The CBF β does not bind DNA, but can interact with CBF α subunits via their Runt domains and this interaction increases the affinity for DNA of the CBF α . AML-1 binds DNA to its consensus sequence TGT/cGGT [133, 134]. AML-1 can also interact with DNA indirectly via interaction with a subset of Ets family members, including PU.1, and via the interaction with C/EBP α [48, 135, 136]. The activity of AML-1 is also regulated post-translationally; AML-1 activity is increased by phosphorylation mediated by ERK1 [137].

AML-1 is expressed in haematopoietic cells, largely restricted to myeloid and lymphoid cells, but is also expressed in nervous tissue, skeletal muscle, and reproductive tissues [33, 138, 139].

Sp1/Sp3

Promoters which lack a TATA box are often dependent on a functional Sp1 site, which can interact with the TATA-binding protein (TBP) [140]. Sp1 (Specificity Protein 1) was the first known sequence-specific regulator of mammalian gene transcription when it was identified by its ability to bind and activate GC-rich sites in the early promoter of the SV40 tumor virus [141]. Sp1 DNA binding is mediated by a characteristic pattern of three zinc fingers

located in the C-terminus of the protein. The N-terminus activates transcription, but also dimer formations and interactions with the general transcriptional machinery [142]. Several studies have identified seven additional members of the Sp family, which are referred to as Sp2-8 [142], which all can bind to GC-rich sequences. Sp3 shows more than 90% identity to Sp1 in the zinc finger DNA-binding region [143]. Some myeloid GC boxes are bound exclusively by Sp1 or Sp3, whereas others can be bound by both factors [144]. Sp1 and Sp3 are both expressed ubiquitously, and they compete for binding to GC boxes in several cell types [142]. Therefore, the ratio of Sp1:Sp3 proteins, rather than the absolute level of either protein, may affect target gene expression. Generally, Sp3 is a weaker transcriptional activator than Sp1, and Sp3 can also act as a repressor [145].

Sp1 and Sp3 are ubiquitously expressed proteins, and studies in mice indicate that Sp1 levels are highest in developing hematopoietic cells, fetal cells, and spermatids [146].

Functional cooperation of Sp1 and PU.1 in myeloid cells is in several cases necessary for maximal activity of myeloid promoters [147] and it is hypothesized that the cooperation between Sp1 and C/EBP α is essential for the promoter activity of the secondary granule protein lactoferrin [91]. As with lactoferrin expression, cooperative activity of Sp1 and C/EBP α may depend on the recruitment of transcriptional co-factors, like p300, which can acetylate histones and transcription factors, including Sp1 [148, 149]. Sp1 and Sp3 are both targets of post-translational modifications. These modifications contribute to their tissue-specific functions. Several kinases can phosphorylate Sp1, like protein kinase A [150]. Phosphorylation of the N-terminus of Sp1 increases its DNA-binding affinity, thereby increasing Sp1 transcriptional activity [151]. Reduced DNA binding and therefore, reduced transcriptional activity is found when the zinc fingers of Sp1 are phosphorylated [152]. Glycosylation of Sp1 affects its nuclear localization and has both positive and negative effects on the transcriptional activity by altering physical interactions with the basal transcriptional machinery. Glycosylation also stabilizes the Sp1 protein; low glycosylation levels appear to initiate degradation [142]. Activity of Sp1 and Sp3 is also regulated by direct acetylation. In the case of Sp1, acetylation has

various effects on the DNA binding and activity [144]. Acetylation of Sp3 is probably necessary for its repressive activity [153], but the effect of this modification on the transcriptional activity of Sp3 is still unclear. Recent work has shown that the single lysine residue in the Synergy Control (SC) motif of Sp3 is a target for sumoylation which is essential for the repressive activity of Sp3 and is in this way involved in the reduced transcriptional activity of Sp3 [154]. Sumoylation means the addition of a small ubiquitin-related modifier (SUMO) to a single lysine residue in a variety of target proteins and this binding can modulate their activity [155].

CCAAT displacement protein (CDP)

CDP is a widely expressed protein that represses gene expression via binding to a CCAAT box and displacing the binding of positively acting factors [156]. CDP is a homeodomain protein with extensive homology to the *Drosophila cut* protein [157]. Recently, it was shown that the DNA-binding activity of CDP depends on proteolytic cleavage that removes the N-terminus of CDP [158].

| Name transcription factor | Family | Demonstrated functional binding to target gene | Cooperative proteins |
|----------------------------------|----------------------------------|--|---|
| PU.1 | ets | MPO (mouse)[25, 70, 71]; Proteinase 3 (human)[74]; Elastase (mouse)[80] | Co-activator c-JUN; GATA-1; RAR; ICSBP |
| C/EBP α | Leucine zipper | MPO (mouse)[25, 70, 71]; Elastase (mouse)[80]; α -defensins (human)[82]; Lactoferrin (human)[87, 91]; Collagenase (human)[92] | Other C/EBP members; NF- κ B; Rel proteins; Sp1 |
| Onspecific C/EBP | Leucine zipper | Proteinase 3 (human)[75] | Other C/EBP members; NF- κ B; Rel proteins; Sp1 |
| C/EBP ϵ | Leucine zipper | Lactoferrin (human & mouse)[87]; Collagenase (human)[92] | Other C/EBP members; NF- κ B; Rel proteins; Sp1; c-myb |
| AML1 | Core Binding protein (CBF) | MPO (human & mouse)[45, 64, 72] | PU.1; C/EBP α |
| Sp1 | Zinc finger | Proteinase 3 (mouse)[77]; MPO (human)[63]; Lactoferrin (human & mouse)[88, 89] | PU.1; C/EBP α |
| RAR α | Superfamily of nuclear receptors | C/EBP ϵ [43] | RXR receptors |
| c-myb | Leucine zipper | Proteinase 3 (human)[75, 76]; MPO (mouse)[72]; Elastase (mouse)[80] | C/EBP members |
| CDP/cut | Homeodomain protein | Lactoferrin (human & mouse)[86] | |

Table 1. Summary of transcription factors involved in myelopoiesis.

C. General aspects of transcriptional regulation

C. 1. The core promoter

The core promoter is a DNA sequence which is located immediately adjacent to and upstream of the gene and downstream of the regulatory promoter as illustrated in **figure 4**. RNA polymerase II (Pol II) and the general transcription factors (GTFs), including TFIIA; TFIIB, TFIID; TFIIE; TFIIF; and TFIIH [159], belong to the general transcription machinery. The general transcription machinery bind the core promoter which directs RNA polymerase II (Pol II) to start the transcription at the correct transcription start site. Generally, the core promoter alone is inactive *in vivo*, but *in vitro* it can bind the general machinery and activate gene expression at low or basal levels. A typical core promoter contains a TATA-box located 25-30 bp upstream of the transcription start site and binding sites for the multisubunit protein TFIID. TFIID is the only general transcription factor capable of binding the core promoter independently and specifically. The TATA-Binding Protein (TBP) together with 10 or more TBP-associated factors (TAF_{II}s) is part of the multisubunit protein TFIID and makes direct contact with the TATA-box [160, 161]. The binding of TFIID to the TATA-box makes it possible for the other general transcription factors and for RNA polymerase II to bind to the core promoter and this complex of proteins, together with coactivators, forms the RNA polymerase II holoenzyme [161, 162].

A second type of core promoter contains an initiator element instead of the TATA-box. Initiator elements are known to show similar functions as the TATA-box. The initiator element overlaps the transcription start site and binding of TFIID to this element is influenced by TFIIA and cofactors called TICs (TAF_{II}-and initiator-dependent cofactors) [163, 164]. Beside the typical core promoter structures with TATA-box or initiator element, a third class of core promoters lack both of these sequences. Instead, these promoters often contain a high G/C content and multiple sites for the ubiquitous transcription factor Sp1 [165]. At these promoters, Sp1 directs the formation of the preinitiation complex to a region 40 to 100 basepairs downstream of its binding sites.

C. 2. Regulatory transcription factors

The transcription factors which are active during myelopoiesis, as discussed above, belong to large group of so called regulatory proteins or regulatory transcription factors (RTFs). These regulatory transcription factors contain a DNA-binding domain which binds the protein to specific sequences (specific *cis*-DNA elements), including the regulatory promoter and enhancer sequences (as illustrated in **figure 4**). The regulatory promoter is located approximately 100-500 basepairs upstream from the core promoter. The enhancer sequence is found at positions up to several thousand upstream from the core promoter, but can also be localized downstream in an intron sequence of the gene. The regulatory proteins contain an transactivation domain which can initiate the gene transcription [166, 167]. The binding of the regulatory transcription factors to the regulatory promoter or the enhancer sequence is generally cooperative, which means that one transcription factor binds weakly, but multiple transcription factors which undergo protein-protein interactions with eachother give rise to increased affinities to DNA and in this way results in stronger gene transcription, also called 'synergy' in transcription [168].

The combinations of the regulatory transcription factors bound to the upstream localized enhancer sequences gives a nucleoprotein structure, called enhanceosome [169]. The enhanceosome recruits chromatin-modifying activities and interacts with the general transcription machinery and recruits it to the core promoter to form the preinitiation complex. The link between the proteins of the enhanceosome and the proteins of the general transcription machinery can be done by a mechanism called DNA-looping. Beside the looping of DNA, there are also other mechanisms that make it possible for enhancer sequences and their bound proteins to work at a distance and in this way activating the transcription. These mechanisms include nucleosomal rearrangements, done by proteins sometimes called coactivators [170, 171].




Figure 4. Schematic representation of the gene structure and the proteins involved in the initiation of gene transcription. Legend: Pol II, RNA polymerase II; GTFs, General Transcription Factors; RTF, Regulatory Transcription Factors, TS, Transcription start site.

C. 3. The activation or repression of a gene

Genes in an inactive state are tightly assembled into chromatin composed of histones, which form together a structure called a nucleosome. The histones can be modified post-translationally resulting in conformational changes of the nucleosome. Inactivated genes are often methylated and this methylation leads to binding of enzymes, called histone deacetylases (HDACs) [172]. Histone deacetylases (HDACs) are enzymes which are responsible for the deacetylation of the histone proteins of the chromatin structure and makes genes transcriptionally inactive. In contrast, the histone acetyl transferases (HATs) are enzymes involved in the acetylation of histones and has been associated with transcriptionally active genes. Remodeling of chromatin, like decondensation and acetylation of its histones, is crucial for the binding of RNA polymerase II (Pol II) and the whole preinitiation complex, because genes are not accessible for transcription factors when they are assembled into condensed or deacetylated chromatin [173]. The mammalian coactivator, p300 and its related homolog CBP, for example, are able to recruit histone acetyl transferases (HATs) [171], while corepressors like SMRT are associated with histone deacetylases (HDACs) [174-176]. During myelopoiesis for example, in the absence of the ligand retinoic acid (RA), the corepressors, like SMRT are bound with HDACs, while binding of retinoic acid (RA) to its receptor induces the release of these corepressors and induces the binding of coactivators with

HATs [177]. The latter leads subsequently to the initiation of transcription of some myeloid-specific genes [38].

The activation of a differentiation-related gene is in general transient and therefore genes may be dynamically turned on and off, as for example during the differentiation program of myeloid cells in the bone marrow. The inactivation of a gene, also called repression, can, besides methylation and deacetylation, involve other types of mechanisms. First, it can occur by inactivation of a regulatory transcription factor by post-translational modifications or dimerization of the regulatory transcription factor with a nonfunctional protein or by competition for a binding site. The tagging or binding of a small protein, called ubiquitin, to the transcription factor can lead to the destruction of this transcription factor by the proteasome [178]. Secondly, repression can be mediated by inhibition of the preinitiation complex; and finally, repression can involve the binding of sequence specific repressors to silencer elements [179]. Corepressors can interact with the same DNA-binding transcription factor and in this way, a single DNA sequence can both mediate activation and repression of the transcription of a gene.

D. Proteins and peptides and their role in innate immunity

D. 1. The migration of mature leukocytes to sites of infection

The polymorphonuclear neutrophils (PMNs) and monocytes/macrophages play a central role as phagocytic cells in the first line of defense and are important components of the innate immunity [180] [5, 181]. Following release from the bone marrow into the blood circulation, mature neutrophils are incapable of cell division, stay very shortly (about 6-10 hours) in the circulation and subsequently migrate into the tissues, where they undergo spontaneous apoptosis after 1-2 days [2, 182]. In response to inflammatory stimuli, neutrophils become activated and migrate from the circulating blood to infected tissues, where they efficiently bind, phagocytose, and kill bacteria and other invaded microbes [183, 184]. Monocytes can also be activated upon stimulation

of inflammation, they migrate and differentiate into macrophages in the infected tissues and play their roles as long-lived (several months or even years) phagocytes [1, 184].

The migration of leukocytes (or phagocytic cells) from the circulating blood to sites of infection in the extravascular tissues involves a series of sequential events regulated by several molecular interactions [185, 186]. The first steps in this migration process involve tethering to and rolling of the leukocyte along the endothelial cells of the vessel wall. This slowing down of leukocytes is mediated by weak and reversible molecular interactions between the selectins of the leukocytes and endothelial cells [185, 186]. Other inflammatory factors (chemokines, cytokines), such as platelet-activating factor (PAF), IL-8, fMLP, TNF- α , IL-1 β , and LPS, bind to receptors on the cell membrane of the phagocytic cells and activate them to express integrins on the cell surface [187]. Integrins, together with selectins, make the phagocytic cells tightly adherent to the endothelial cell wall. After shape change and polarization, the leukocytes migrate through the endothelial cell wall, penetrate the basal membrane, the extracellular matrix of the connective tissue to reach the infected extravascular tissue.

D. 2. Antimicrobial proteins and peptides in phagocytic and non-phagocytic cells

Killing and destruction of microorganisms after phagocytosis is mediated by an NADPH- dependent oxidase that transfers electrons from NADPH to oxidase (O_2) to form oxygen radicals (O_2^-), a reaction called 'respiratory burst' [188]. Oxygen radicals are converted to hydrogen peroxide (H_2O_2) which with the help of the azurophil granule protein myeloperoxidase (MPO) is converted to hypochlorous acid (HOCl), the most bactericidal agent produced by the neutrophil [189]. Macrophages also possess this oxygen-dependent mechanism to kill microorganisms [190], but do also, together with the neutrophils, contain a wide range of oxygen-independent antimicrobial proteins and peptides [191, 192]. Antimicrobial proteins and peptides of the neutrophil are largely stored in the azurophil and specific granules. The specific granules release their contents

both into the phagosome and into the extracellular environment, while the azurophil granules degranulate into the phagosome, where the ingested or phagocytosed microorganisms are directly exposed to high concentrations of granule contents. Antimicrobial agents in the neutrophil granules may also be released into inflammatory fluids following necrosis of the neutrophil [192]. Neutrophil granule proteins with antimicrobial activity include lactoferrin [193-195]; BPI (see next section), proteinase 3 together with other serine proteases [196, 197]. The antimicrobial peptides belong to two main peptide families: the defensins and the cathelicidins [198-200]. These peptides are not only found in phagocytic cells, but are also produced in various types of epithelial cells and nonphagocytic cells [201]. Defensins are of two main classes: the α -defensins and the β -defensins. Of the six known human α -defensins, four (human neutrophil peptide, HNP-1-4) are expressed primarily by neutrophils, but they are also expressed in specific lymphocyte and monocyte subpopulations [202]. The other two, HD-5 and -6, are expressed by intestinal Paneth Cells [203, 204]. In humans, four types of β -defensins have been identified (HBDs 1-4). HBD1 and 2 are mainly synthesized by epithelial cells, but expression of HBD1 and 2 mRNA occurs also in monocytes and monocyte-derived macrophages [204, 205]. Among rodents, mice lack leukocyte defensins [206], rats have them [207], and both species have numerous Paneth cell defensins (called Cryptidins in mice) and epithelial cell β -defensins [208-211].

The combined action of oxygen-independent antimicrobial proteins and peptides results in an attack of the microbial membrane and/or cell wall, leading to growth arrest and death of the invaded microbes. And, in some cases, like for BPI and lactoferrin, the binding to lipopolysaccharide at the outer membrane of gram negative bacteria leads to neutralization of this endotoxin (LPS) [195, 212].

D. 3. Human BPI

Human BPI, a 55-kDa protein, was isolated from polymorphonuclear neutrophils (PMNs) in 1978 by Elsbach, Weiss and colleagues [213], but it took almost 20 years until the crystallized structure of the full-length recombinant human BPI (Bactericidal/Permeability-Increasing protein) was studied [214]. The BPI gene is localized to chromosome 20 [215] and is composed of 15 exons ranging in size from 43 bp (exon 12) to 358 bp (exon 15) with 14 introns ranging in size from 0,6 kb (intron 8) to 6,6 kb (intron 5) [216]. Cloning and sequencing of BPI cDNA has revealed a predicted protein structure with a basic, hydrophobic N-terminal and an acidic, hydrophilic C-terminal. Together with the α -defensins (HNP 1-4), proteinase 3 and azurocidin, BPI is stored in the cytoplasmic azurophil granules of PMNs. BPI may with its hydrophobic C-terminal domain be attached to the membrane of the azurophil granules and to the cell membrane of the neutrophils (PMNs) [10, 217].

BPI is also present in lower amounts in specific granules of human eosinophils [218]; on the surface of human peripheral blood monocytes [219]; in human mucosal/colon epithelial cells [220] and in human dermal fibroblasts [221]. The expression of BPI in epithelial cells was, however, only detectable upon stimulation with inflammatory stimuli [220, 221].

BPI shows activity against gram-negative bacteria and does this in three ways: (1) it shows a cytotoxicity via sequential damage to bacterial outer and inner lipid membranes [222]; (2) it neutralizes the gram-negative bacterial surface lipopolysaccharide (LPS) or endotoxin [223] and (3) it opsonizes bacteria to enhance phagocytosis by neutrophils [224]. See **figure 5** for a schematic overview. Binding of BPI to the surface of gram-negative bacteria involves electrostatic interactions between the cationic N-terminus of BPI and the negatively-charged phosphate groups of LPS [225]. The cytotoxic effects of BPI on gram-negative bacteria are synergistically enhanced by members of the defensin family [226].

It was reported that intracellular BPI content is 3-to 4-fold higher in adult neutrophils than in newborn neutrophils and this may contribute to the increased incidence of gram-negative sepsis among newborns. However, other

studies show that only 40% of newborns have a BPI-deficiency, while others have normal levels of intracellular BPI [227].

BPI is also a target antigen of anti-neutrophil cytoplasmic autoantibodies (ANCA). The presence of anti-BPI autoantibodies (BPI-ANCA) was first detected in patients with Wegener's Granulomatosis, but are also found in diseases such as inflammatory bowel disease, ulcerative colitis and cystic fibrosis. This BPI-ANCA may make the inflammation worse by reducing the ability of BPI to destroy the gram-negative bacteria and to neutralize bacterial LPS. BPI-ANCA is associated with a higher inflammatory disease activity and greater organ damage [228].

In a randomized clinical trial, the treatment of patients having meningococcal sepsis with recombinant 21 kDa N-terminal BPI fragment (rBPI₂₁) has been shown to be beneficial in decreasing complications of meningococcal disease, such like necrosis which can lead to amputations [229].

D. 4. Similarities and differences between LPS-binding protein and BPI

The LPS-binding protein or LBP is constitutively secreted into normal plasma by the liver and its expression can be induced during an early phase of a gram-negative bacterial infection, also called the acute phase response. LBP transfers LPS to CD14 on the cell surface of monocytes/macrophages [232, 233]. CD14 can, via MD-2, activate the Toll-like receptor-4 (TLR-4) that in its turn transduces a signal leading to the secretion of pro-inflammatory mediators, such as TNF- α and IL-1 β , which trigger the inflammatory reaction [234, 235]. See **figure 5** for a schematic overview.




Figure 5. Modified from Levy O., 2000. GNB: gram-negative bacteria;
 BPI: Bactericidal/Permeability-Increasing protein; LBP: LPS-Binding Protein;
 LPS: lipopolysaccharide.

BPI (Bactericidal/Permeability-Increasing protein) and LBP (LPS-binding protein) bind both the lipid A [212, 236], but BPI function as an antagonist of the LBP-LPS interaction [237]. At sites of infection, a molar excess of BPI is present and here can BPI fulfill its functions extracellularly by binding to LPS leading to the neutralization of the endotoxic effect [223]. BPI and LBP are related proteins [238] encoded by genes localized in a cluster on human chromosome 20 [215] and the genomic structure (exon-intron organization) of BPI and LBP shows strong sequence homology to each other, implying a common origin of these genes [216]. Recently, BPI and its relative LBP was also found to be expressed in epithelial cells [220, 221, 239], which are not only known as mechanical barrier-cells, but are also found to have a secretory function in the first line of defence in the host [240].

D. 5. BPI and its relatives

BPI (Bactericidal/Permeability-Increasing protein) and LBP (LPS-binding protein) belong to a related protein family, including CETP (Cholesteryl Ester Transfer Protein) and PLTP (Phospholipid Transfer Protein) [241]. BPI and LBP, as described above, function as antagonists in the innate immune response against gram-negative bacteria. The two other proteins, CETP and PLTP are produced by the liver and function in the transport of lipids between lipoprotein particles in the bloodstream and do not have any known function in the innate immune system [242]. BPI, LBP and PLTP are encoded by related genes located on chromosome 20, while the CETP gene is located at chromosome 16 [241].

A novel family of secreted proteins, named PLUNC (palate, lung and nasal epithelial clone) proteins, was recently identified and these novel proteins are expressed in the upper airways (respiratory tract), nose (nasal), and mouth (oral) [243, 244]. The family of PLUNC proteins is encoded by related genes localized in a cluster on human chromosome 20 [243] and in a cluster on mouse chromosome 2 [245]. The proteins of the PLUNC family show very low primary amino acid sequence identity (below 40%), but are predicted to be structurally similar to BPI and LBP [214, 244]. Based on its expression pattern and the structural similarities with BPI and LBP, it is suggested that PLUNC proteins play a potential role in the innate host defense, but the exact function is still not known [241]. The mouse orthologs of the human PLUNC proteins are specifically expressed in the tongue and minor salivary glands and the mouse PLUNC family includes PSP (parotid secretory protein), VEMSGP (von Ebner minor salivary gland protein), SPLUNC1, and SPLUNC5 [246]. Because of the identification of many new PLUNC-genes in different species, PLUNC was renamed as SPLUNC1 [247], which not should be mixed up with the subdivision of the 'old' PLUNC protein family into two subgroups, the short PLUNC (SPLUNC) and the long PLUNC (LPLUNC), based on the primary sequence length and the structural predictions [244, 247]. The short PLUNC proteins (\approx 200 amino acids) show similarity only with the N-terminal domain of BPI, whereas the long PLUNC proteins (\approx 400 amino acids) are similar to both the N- and C-terminal domains of BPI and LBP [244]. Another newly

identified family of proteins related to BPI and PLUNC are the RY proteins. These RY proteins are also suggested to have potential functions in the innate immune system and show conservation between human and mouse [248].

D. 6. Proteinase 3 and its role in Wegener's Granulomatosis (WG)

Proteinase 3 (PR3), also called myeloblastin [249], is a 29-kDa serine protease stored in the azurophil granules of the polymorphonuclear neutrophils (PMNs) and in the granules of monocytes [250]. Besides azurophil granules, PR3 is also stored in specific granules, secretory vesicles and is present on the plasma membrane of resting and unactivated neutrophils [251, 252]. During phagocytosis, PR3 has an antimicrobial activity, similar to the activity of other serine proteases, cathepsin G and neutrophil elastase (NE), and this activity is both against gram-negative - and gram-positive bacteria, as well as against fungi [197, 253]. Like neutrophil elastase (NE), PR3 may play a role in the migration of neutrophils through the basal membranes and is able to degrade a variety of extracellular matrix proteins and basal membrane proteins [197, 254]. PR3 may also be involved in processing of inflammatory mediators such as processing of cytokines like TNF- α [255] and IL-8 [256] and it induces the production of IL-8 by endothelial cells [257].

PR3 is the main target antigen of antineutrophil cytoplasmic autoantibodies (ANCA) observed in Wegener's Granulomatosis (WG) [258-260]. Wegener's Granulomatosis (WG) is an autoimmune chronic inflammation that appears in several organs (kidney, nose, and lung), therefore also called 'systemic' vasculitis and is characterized by chronic inflammation of the small blood vessels, leading to necrosis in the organs which are supplied by the damaged vessels [261]. The antineutrophil cytoplasmic autoantibodies (ANCA) are strongly associated with small-vessel vasculitis or Wegener's Granulomatosis (WG), but the exact role of these autoantibodies is not yet known [262]. Increasing evidence indicate, however, that PR3-ANCA are involved in the pathogenesis of WG [263]. Not only PR3-ANCA, but also antibodies specific against myeloperoxidase, and other granule proteins, such as BPI, are found in patients with systemic small vessel vasculitis [264-267].

The membrane expression of PR3 is heterogeneous for circulating (resting) neutrophils of healthy persons and defines two neutrophil populations: with and without PR3 surface expression, respectively [252]. The proportion of PR3⁺ neutrophils and PR3⁻ neutrophils varies among individuals, is stable over prolonged time and is genetically controlled [252, 268]. In WG patients, an increased percentage of PR3⁺ neutrophils and an elevated level of PR3 expression as compared with healthy individuals was found and level of PR3 expression was correlated to increased relapse rate [269]. This observation has led to the hypothesis that an increased number of PR3⁺ neutrophils and increased amount of PR3 molecules on neutrophil membrane could be a risk factor and could play a role in the pathogenesis of WG [270].

The observation that inactivated neutrophils show PR3 expression on their membranes is controversial to other studies which only found PR3 expression on the surface of primed or pre-activated neutrophils [271, 272] and Yang *et al* argues that the neutrophil isolation procedures itself cause an '*in vitro*' stimulation which explains that other researchers, like Halbwachs-Mecarelli *et al*, found PR3 expression on the plasma membrane of resting neutrophils.

A mechanism which possibly could explain the role of PR3-ANCA in the pathogenesis of WG is as follows: Priming or pre-activation of neutrophils with pro-inflammatory cytokines, such as TNF- α , induces the translocation of PR3, and probably also other target antigens, such as MPO, from the cytoplasm (stored in granules or vesicles) to the plasma membrane, where these antigens are accessible to ANCA [272, 273]. Binding of ANCA to PR3 (or to the other target antigens) triggers signaling events that lead to neutrophil activation, causing an increase in respiratory burst (NADPH-oxidase activity), but also degranulation with the release of more PR3 and other serine proteases and production of IL-1 β . These effects of the neutrophil activation leads then to damage of the endothelial cells of the vessel wall [274, 275]. It is generally assumed that ANCA interacts with PR3 via the Fab region of the antibody and its Fc region interacts with the immunoreceptor Fc γ RIIa on the neutrophil cell membrane, leading to the cross-linking of PR3 to Fc γ RIIa [276, 277]. Fc γ RIIa is a transmembrane protein with a tyrosine-based activation motif in its cytoplasmic domain [278] and the process of cross-linking to PR3 lead in its

turn to the activation of intracellular signaling pathways which induces the respiratory burst (or increased expression of NADPH-oxidase). The exact signaling mechanisms are not fully known yet, but some studies indicate a tyrosine kinase dependent pathway, involving PI3-K, PKB/Akt and ERK [279-281], but it may also occur via a tyrosine kinase independent pathway, involving PKC [282]. Integrins in the plasma membrane of neutrophils may also be activated by ANCA and increase the adhesion of the activated neutrophils during vasculitis [283]. Another hypothesis is that ANCA antigens are expressed on the surface of apoptotic cells, get then phagocytized by macrophages, which in their turn become hyperactivated, leading to increased secretion of pro-inflammatory cytokines and may play a role in the amplification of the inflammatory process in WG [271, 284]. This hypothesis, leads us further to the potential role of monocytes in the pathogenesis of WG [285]. One study suggests that pro-inflammatory cytokines induces translocation of intracellular stored PR3 to the membrane of monocytes, makes them accessible to ANCA, with consequences similar to those for neutrophils [272]. Recently, Ohlsson *et al* [286] found an increased PR3 mRNA expression in peripheral monocytes from patients with AASV (ANCA-associated small vessel vasculitis) as compared to healthy persons. However, this increase in PR3 mRNA could not be explained by the induction of pro-inflammatory cytokines, as suggested in previous studies [287, 288]. Yang *et al* found not only an increase of PR3 mRNA in monocytes, but also in neutrophils of patients with AASV [289].

II. Aims of the present studies

The four different studies I-V are numbered according to papers I-V, and the specific aims are as follows:

Study I:

- To identify the transcription start site of the human BPI gene in myeloid cells.
- To clone the proximal promoter of the human BPI gene.
- To identify functional elements within the cloned promoter which play important roles in the transcriptional regulation of human BPI gene during myelopoiesis.

Study II:

- To investigate whether BPI is structurally and functionally conserved between humans and mice.
- To study the expression profile of the mouse BPI and to compare the expression levels in different tissues between humans and mice.

Study III:

- To identify the transcription start site of the mouse BPI gene in myeloid cells.
- To clone the proximal promoter of the mouse BPI gene.
- To characterize the cloned promoter region for potential cis-elements and compare these elements with those found within the human BPI promoter

Study IV:

- To investigate if the SNP (Single Nucleotide Polymorphism) which introduces a new potential Sp1 transcription factor binding site may be responsible for the observed up-regulated expression of proteinase 3 (PR3) in myeloid cells of Wegener's Granulomatosis patients.

III. Experimental considerations

A. Determination of the transcription start site

Localization of the proximal promoter region can be done by determination of the transcription start site, because the promoter region is by definition located close to and upstream of the transcription start site [172]. 5'RACE, which means 5'Rapid Amplification of cDNA ends, is a technique used to localize the transcription start site by identification of the 5' end of the encoded mRNA. A potential risk of this technique, however, is degradation of mRNA leading to inaccurate determination of the transcription start site. Therefore, it was of interest to also use an alternative to the conventional 5'RACE, namely the 5'RML-RACE technique. In 5' RML-RACE, the poly (A) mRNA is first treated with Calf Intestine Alkaline Phosphatase (CIP) to remove all the free 5' phosphates from degraded mRNA, ribosomal RNA and contaminating genomic DNA. The cap structure, which is found on intact or full-length mRNA protects intact mRNA from CIP, but is removed by Tobacco Acid Pyrophosphatase (TAP), which in its turn leaves a monophosphate at the 5' end of the mRNA. The next step, which is in common with the first step in the conventional 5' RACE method, is the ligation of an adaptor to the mRNA. In 5' RML-RACE, this ligation can only take place on intact mRNA with its 5' monophosphate and not on dephosphorylated sample material. Both methods, 5' RACE and 5'RML-RACE, will transcribe the adaptor-ligated mRNA to cDNA, which will be subsequently amplified in two nested PCR reactions using specific PCR primers which are complementary with the known cDNA sequence of the gene of interest.

A good starting point when using both 5' RACE methods, is to use cells or cell lines which express high levels of the specific transcript of interest. Human mononuclear bone marrow cells and the human promyelocytic cell line HL60 express high levels of BPI mRNA, which was an advantage when using 5'RACE. For the mouse promyelocytic MPRO.C1 cell line, I was forced to first treat the cells with ATRA to reach mRNA levels of BPI which were high enough to proceed with 5' RACE. I also tried to use

mRNA extracted from the ATRA-treated 15P-1 cells (mouse Sertoli cell line) for 5'RACE, but this trial was unsuccessful, probably because 15P-1 cells express much less of the specific BPI transcript, as compared to the MPRO.C1 cells, although 15P-1 cells respond in a similar way to ATRA as MPRO.C1 cells (**Paper II**).

A complementary method to 5'RACE is primer extension analysis, which was not used in this thesis. By using primer extension, only two specific reagents are required: a mRNA sample and a radiolabeled oligonucleotide primer which can bind complementary to the specific mRNA sequence. The resulting radiolabeled cDNA is then analyzed on a denaturing polyacrylamide gel electrophoresis and the size of the band detected on the gel, as compared with a molecular weight marker, gives us a determination of the distance between the site where the primer is bound, and the beginning of the mRNA transcript. Primer extension is less sensitive than 5'RACE, because it is not a PCR-based method, but is more quantitative than 5'RACE and can therefore give us an idea about the level of transcriptional activity in the investigated cells or cell lines.

A disadvantage of the primer extension analysis is that it does not provide sequence information regarding the transcript. Therefore, no alignment to genomic DNA can be performed. If the primer not binds in the sequence corresponding to exon 1, the transcription start can be inadequately determined to be localised in intronic sequences. 5'RACE, on the other hand, provides sequence information on the transcript and therefore in this respect is superior to primer extension analysis.

B. Measurement of transcriptional activity

The promoter strength (or level of promoter activity) is generally considered to be proportional to the number of specific mRNA transcripts synthesized per time unit by the RNA polymerase II [172]. An indirect way to measure promoter activity is the reporter assay in which determination of enzyme levels is used as an indirect measurement of promoter activity. In this thesis, I used the luciferase reporter assay in which the promoter region of interest

is inserted immediately and upstream of the *firefly* luciferase gene in a so called reporter vector. The inserted promoter is thus able to activate the transcription of the *firefly* luciferase gene and the translated *firefly* luciferase enzyme will then catalyze a reaction resulting in light emission, which then finally can be measured in a luminometer. The most common way, and also the one I used, to introduce the vector into cells is by performing transient transfections. In a transient transfection procedure, the reporter vectors which contain the promoter region of interest are transfected into cell lines and within a short period, typically 10 to 24 hours, but sometimes longer, the enzyme activity is measured. Transient transfections are generally performed in cell lines which express the endogenous gene from which the promoter region is derived. The human BPI promoter showed highest activity in HL60 cells which also were found to express a relative high level of the endogenous BPI gene. The human cervix carcinoma cell line HeLa can be used as a negative control for specific promoter activity, because this cell line did not express detectable amounts of any BPI mRNA transcript. To compare promoter activity between different cell lines, for example between U937 cells and HL60 cells, normalization of specific enzyme activity levels to levels obtained by transfection of control reporter vectors is necessary. A negative control is a transfection with the promoterless pGL3 basic vector, which is also used for insertion of the promoter region of interest. Positive control transfection is performed with a vector containing a strong viral promoter fused to the *firefly* luciferase gene, such as pGL3 promoter. Both vectors, pGL3 basic and pGL3 promoter, are used in this thesis. The level of enzyme activity obtained by transfection of pGL3 promoter gives us an idea about the relative strength of our promoter of interest in the individual cell lines.

To compensate for varying transfection efficiencies between different experiments, internal controls can be used. In our studies, the *Renilla* luciferase reporter vector was used as internal control and was co-transfected with the *firefly* luciferase reporter vector. The *firefly* and *Renilla* luciferases are of distinct evolutionary origins and have different enzyme structures and substrate requirements [290] and it is therefore possible to

specifically determine each of their activity when co-transfected into the same cell population [291].

By using stable transfection assays, which is an alternative to transient transfection assays, the vector containing the reporter gene and the promoter region of interest can be stably integrated in the genome of the transfected cell line. The advantage of the stable transfection assay as compared to the transiently, is that the analyzed promoter is surrounded by a more natural chromatin configuration and at a more natural copy number [292]. A disadvantage is of course that it can be inadequately affected by surrounding promoter and enhancer sequences.

In addition to the indirect reporter assay, a direct way to measure transcriptional activity is to measure the steady-state mRNA levels of the endogenous gene of interest. The steady-state mRNA level is defined by the level of mRNA as a result of its rate of synthesis and its rate of degradation [172]. I have been using three methods in this thesis which are in common to measure the steady-state mRNA levels in cells and tissues. These three methods include Northern blot, the standard RT-PCR and the fluorescence-based real time RT-PCR. Northern blot analysis is based on the gel electrophoresis of total RNA samples and specific mRNA is detected by using labeled oligonucleotide, cDNA or RNA probes. Northern blot analysis is the only method of all three used methods, which gives information about mRNA-size. The second method, the standard RT-PCR (Reverse Transcription - Polymerase Chain Reaction), is a rapid and extremely sensitive way of analyzing whether a gene is expressed or not and can also provide a semi-quantitative information about steady-state mRNA expression levels. RT-PCR is a PCR-based method and is much more sensitive than Northern blot. RT-PCR needs less than 1 μ g of total RNA or 10-100 ng mRNA, while Northern Blot needs 2-20 μ g of total RNA. In RT-PCR, the RNA template is first transcribed into cDNA, followed by its amplification in a standard PCR reaction using sequence-specific primers. The end-products of this reaction are then analyzed by standard agarose gel electrophoresis.

A PCR amplification typically proceeds in three phases, an early slow phase where initial products are formed; a mid phase, in which products are amplified in an 'exponential' manner; and a late phase, where product amplification reaches a plateau, which also involves the end of the PCR reaction. The plateau is reached as a consequence of changes in relative concentrations of certain components of the reaction and therefore some PCR reactions will generate more product than others. In some PCR reactions, the exponential phase may start later, in which more cycles are often needed in order to reach the plateau phase [293]. It is because of these limitations that the analyzing of the end-product in the standard RT-PCR is unreliable as a way to quantitatively analyze differences in steady-state mRNA levels between different cells or tissues.

Therefore, in a third method, the fluorescence-based real time RT-PCR, it is possible to measure the amount of PCR product at a point in which the reaction is still in the exponential phase. During the exponential phase in real time PCR reaction, a fluorescence signal threshold is determined at which point all samples can be compared. This threshold is called cycle threshold, or C_t , and is defined as the number of PCR cycles required to generate enough fluorescence signal. The C_t value is directly related to the amount of RNA template and is therefore the basis for calculating steady-state mRNA expression levels [294]. In the mouse BPI ortholog study, relative expression levels of steady-state mRNA were determined by calculating the differences in the C_t values (ΔC_t) of the genes of interest before and after treatment with ATRA. The expression level of the house-keeping gene β_2 -microglobulin was used as normalization before calculating the relative expression differences. Due to the exponential nature of real time PCR, the ΔC_t is converted to a linear form by $2^{-(\Delta C_t)}$.

In this thesis, we only measured transcriptional activity by an indirect reporter assay and by measuring steady-state mRNA expression levels, but it could also be of interest to consider the analysis of transcriptional activity by measurement of the *de novo* RNA expression. The nuclear run-on assay, for example, is a method based on the measurement of the *in vivo* rate of transcription initiation from a specific gene. Briefly, isolated cell nuclei are

mixed with radioactive NTP to label the DNA-bound polymerase molecules and the amount of specific radiolabeled pre-mRNA is then measured by autoradiography [172]. The nuclear run-on assay shows results that are not influenced by mRNA degradation and can give a strong indication if the expression of a gene is regulated at the level of transcription or at the level of mRNA stability. In general, gene expression is not only regulated at the level of transcription, but can also be controlled by the intrinsic stability of mRNA. The amount of time required for 50% of the mRNA to degrade is called half-life and this can be short or long for a given mRNA. Many studies are available to measure mRNA stability or degradation, including the inhibitor studies with a substance called actinomycin D, which can enter the cells and can block transcription. The amount of intact mRNA remaining at various time points after addition of actinomycin D can be analyzed and gives an answer about the half-life of the mRNA [172].

If the promoter activity, as indirectly measured by luciferase activity, is strong and in good correlation with the steady-state mRNA expression levels found by real time RT-PCR, standard RT-PCR or Northern Blot, the gene is most likely regulated at the level of transcription.

C. Determination of the functional importance of transcription factors

C. 1. Deletion analysis

To get better understanding about the transcription factors which are functionally involved in the regulation of the endogenous gene expression, we analyzed the promoter region of interest in a first step by deletion analysis. Deletions of a promoter region can be made by PCR, but also by using the enzyme Exonuclease II, and the resulting deletion mutants, which can be five or more different-sized promoter fragments, are then inserted in the luciferase reporter vector, respectively, and tested for promoter activity by performing transient transfections.

C. 2. Computer-based search for potential cis-elements

The next step in the investigation of the functional importance of transcription factors (trans-elements) in the regulation of the expression of the endogenous gene, is the identification of binding sites (cis-elements) in the cloned promoter region of interest. We identified potential cis-elements within the sequence of the deletion mutants with highest promoter activity by using a Transfac database. Many different internet-based search programs are available to screen promoter regions of interest for possible functionally relevant cis-elements. The binding sites for transcription factors are in general short, 5 to 12 basepairs, and sequence variation within one functional binding site occurs and as a consequence many different transcription factors, from different families or within the same family, can bind to overlapping consensus sequences. In other words, one consensus sequence found in the Transfac database can be potentially recognized by different transcription factors.

Although it is impossible to completely rely on database findings, the search for potential binding sites in databases is interesting to get some information about which types of transcription factors that possibly can play a role in the regulation of a gene of interest. For example, the database search shows transcription factors which are already known to play a role in the regulation of other related genes and therefore may be involved in the regulation of the expression of the investigated gene.

C. 3. Site-directed mutagenesis

Based on the findings of some potential binding sites in the promoter region by Transfac database search, we made a selection of some interesting binding sites and analyzed these individual sites by substitution analysis prepared by site-directed mutagenesis. In site-directed mutagenesis, 3 to 5 nucleotide basepairs within a consensus sequence are replaced by 3 to 5 other nucleotide basepairs by PCR and the mutated promoter is then inserted in the luciferase reporter vector and tested for activity in transient transfections assays. If the mutations reduce the activity of the promoter region, the results suggest that the individual binding site play role in the activation of the promoter region, but is still not an

answer if these individual sites also play a role in the transcriptional regulation *in vivo*.

C. 4. EMSA

The identified, but still potential, transcription factors can then in a next step be analyzed in Electrophoretic Mobility Shift Assay (EMSA) to reveal if these proteins are able to bind to the specific DNA sequence in the promoter region of interest. EMSA is an *in vitro* assay and is based on the principle that a ³²P-labeled DNA probe containing the potential specific binding site is incubated with nuclear extracts containing DNA-binding proteins. The resulting protein-DNA complexes are separated from the free (unbound) DNA by electrophoresis through a nondenaturing polyacrylamide gel as these complexes migrate more slowly than the free DNA probe. An image of the gel is used to detect the positions of the free and bound DNA probe and the protein-DNA complex results then in a specific shift on the gel image [295]. The identification of the specific transcription factor bound to the DNA probe can be done by addition of a specific antibody to the protein-DNA complex. This latter complex migrates more slowly than the complex without antibody and the image of the gel shows a so called supershift.

Also here, in EMSA, nucleotide substitutions can be made in the radiolabeled DNA probe to see if this mutagenesis leads to the disruption of the protein-DNA complex. To get more evidence for the specificity of the binding to the DNA, competition experiments can be performed, where the radiolabeled wild-type DNA probe is incubated with increasing concentrations of unlabeled wild-type and mutant DNA probes. The specific shift of the radiolabeled protein-DNA complex decreases in the presence of increasing concentrations of the unlabeled wild-type DNA probe, because the amount of DNA-binding proteins bound to the unlabeled wild-type probe is higher than for the labeled probe. In contrast, in the presence of the unlabeled mutant DNA probe, the specific shift of the radiolabeled protein-DNA complex does not disappear or do not decrease.

EMSA is a very sensitive method which not only can reveal the binding of a specific transcription factor to its binding site, but also gives an answer if the specific transcription factor is present in high or low concentrations in the

extracted nuclei. Beside its advantages of being a quantitative and semi-quantitative method, EMSA is an assay performed *in vitro* and reveals therefore not if the protein-DNA binding is also functionally relevant *in vivo*. But, if the nucleotide substitution made in the DNA probe in EMSA is similar to the nucleotide substitution made in the promoter fragment in the indirect reporter assay, there is a strong evidence that the disruption of the protein-DNA complex is correlated with the reduced promoter activity and that the analyzed and specific binding site is also functional *in vivo*.

C. 5. ChIP

As a complement to EMSA, an *in vivo* assay, which we didn't use in this thesis, called Chromatin Immunoprecipitation (ChIP), and can be performed to study which cis-elements are functionally important in the nucleus of the living cells [296, 297]. The basic principle of ChIP is as follows, living cells growing in their medium are cross-linked by addition of formaldehyde and for the extraction of the fixated protein-DNA complexes, cells are lysed. These fixated protein-DNA complexes are then immunoprecipitated using specific antibodies against the potential DNA-binding protein. After washing and eluting of the immune complexes, the cross-links between protein and DNA are disturbed and the immunoprecipitated DNA is recovered and used as template in a standard PCR reaction using sequence-specific primers overlapping the potential binding site. As negative control, DNA precipitated without specific antibody is used as template in the same PCR reaction. PCR products are analyzed on a standard agarose gel and a band appears when the specific antibody has bound to the DNA-binding protein of interest. The disadvantage of this *in vivo* ChIP assay is its extreme sensitivity of the PCR which makes that there is an increased risk for nonspecific precipitated DNA even in the negative control without addition of specific antibody. The sequence-specific primers in the PCR reaction can also anneal to nonspecific precipitated DNA in the negative control, so an optimization of the PCR conditions is always necessary here (e.g. cycle number).

C. 6. Overexpression of recombinant transcription factor

To test further the functional importance of the transcription factors for the regulation of the endogenous gene expression, a correlation can be made between results obtained by EMSA and those obtained by the ectopic expression of the DNA-binding protein of interest together with the reporter vector in transiently transfected cells. The choice of the transcription factor to be overexpressed was done from the site-directed mutagenesis studies and the functional binding studies in EMSA. If the overexpression of the specific transcription factor gave an effect on the promoter activity in the transfected cells, one could make the suggestion that the transcription factor is also involved in the *in vivo* promoter activation. We also analyzed the effect of the overexpression of a transcription factor on the steady-state mRNA expression of the endogenous gene. If an induced or repressed steady-state mRNA expression was demonstrated as compared to control mRNA levels, we could conclude that the transcription factor had a negative or positive effect on the expression of the endogenous gene.

Although all the methods used in this thesis to investigate the functional importance of some interesting transcription factors were performed *in vitro*, the combinations of all these methods can give results that suggest that the transcription factors are involved in the regulation of the endogenous gene at the transcriptional level.

IV. Results and general discussion

A. The BPI promoters

A.1. Are the promoters of the human – and mouse BPI genes comparable? (Paper I, II, and III)

The binding of transcription factors to specific regulatory sequence elements is one important mechanism for regulation of granule protein expressing during myelopoiesis [95].

In **paper I**, we set out to identify regulatory cis-elements important for myeloid-specific expression of the human BPI gene and found important functional binding sites for AML1, Sp3, and PU.1, using a combination of *in vitro* experiments as described in the experimental considerations. The identified cis-elements are located within 159 bp upstream of the translation start. The human myeloid leukemic cell lines HL60 clone 15, K562, NB4, and U937 were used as experimental models to demonstrate the myeloid-specific activity of the proximal promoter of the human BPI gene. The BPI promoter was inactive in the non-myeloid HeLa cell line. A correlation between promoter activity and endogenous gene expression was found, in as much as that the promoter showed highest activity in HL60 cells, also showing robust expression of endogenous BPI. U937, NB4 and K562 showed lower promoter activity and also a weaker expression of endogenous BPI, as judged by Northern Blot and RT-PCR. By performing transient ectopic expression of the transcription factors C/EBP α or C/EBP ϵ in HeLa cells we also demonstrated not only an induction of promoter activity, but also an induced expression of the endogenous BPI gene, indicating an important role for C/EBP α and C/EBP ϵ in transcriptional regulation of human BPI.

Almost parallel with the investigation of the transcriptional regulation of human BPI gene, we cloned the mouse ortholog to BPI and found that mouse BPI-mRNA is present in testis, epididymis, bone marrow, as well in the mouse Sertoli 15P-1 and the mouse promyelocytic MPRO.C1 cell lines (**Paper II**). However, low expression levels of BPI in mouse bone marrow cells, as compared to the expression levels in human bone marrow cells

(**Paper II**), indicate important differences in the transcriptional regulation between human-and mouse BPI gene. To further investigate this hypothesis, we cloned the promoter region of the mouse BPI gene (**Paper III**). To localize the promoter region of the mouse BPI gene, we used 5' RML-RACE, and found two alternative transcription start sites, which is analogous to what we found in the human BPI gene (**Paper I**). Transient transfection of five different progressive 5' deletion mutants of the mouse BPI promoter into Sertoli 15P-1 and the promyelocytic MPRO.C1 cells showed strongest promoter activity for the 304 bp –and 166 bp long deletion mutants. The shortest deletion mutant of 27 bp showed only 50% of the maximal promoter activity, which indicates a lack of some critical regulatory *cis*-elements, important for the activity of the 166 bp fragment. Based on the result of this indirect luciferase reporter assay, we used the internet-based Transfac program to search for potential transcription factor binding sites in the 166 bp promoter fragment, as we also did in the case of the promoter of the human BPI gene (**Papers I and III**). Potential binding sites for c-myb, USF, NF- κ B, MZF-1, GATA-1, AML1, and Sp1/Sp3 were found in the mouse BPI promoter and some of these potential sites were similar to those found in the human BPI promoter.

The lack of potential C/EBP binding sites in the mouse BPI promoter provide a possible explanation for the low expression of BPI mRNA in mouse bone marrow cells, as compared to the high expression levels of BPI mRNA in human bone marrow cells (**Papers I and III**). The human BPI promoter contains a functional and important C/EBP binding site at position –100 upstream of the translation start (**Paper I**). The importance of this C/EBP site is strengthened by the finding that the transcription factors C/EBP ϵ and C/EBP β bind to the human BPI promoter in ATRA-treated NB4 cells [298], indicating an important role for C/EBP transcription factors in the differentiation-related expression of human BPI in myeloid cells. Since C/EBP ϵ is an ATRA-responsive gene containing a RARE (Retinoic Acid Response Element) within its promoter [43], C/EBP ϵ might be a link between ATRA and human BPI expression. The treatment of the mouse promyelocytic MPRO.C1 cell line with ATRA similarly induced mouse BPI

mRNA expression, and the effect of ATRA was partly dependent of *de novo* protein synthesis. A similar induction of the mouse BPI mRNA was seen in the ATRA-treated Sertoli 15P-1 cells (**Paper II**). These results suggest that also the mouse BPI gene expression is differentiation-related, but, however, no potential RARE, neither potential C/EBP site, was identified in the cloned mouse BPI promoter region (**Paper III**). It is possible that the ATRA-response is mediated by a RARE located in a more upstream regulatory element. The human proximal BPI promoter does also not contain a potential RARE, but here an indirect effect of ATRA was shown by the binding of C/EBP ϵ as already mentioned. Consistent with the absence of RAREs in the proximal promoter of both human and mouse BPI, it was not possible to demonstrate ATRA-responsiveness using the indirect luciferase reporter assay (data not shown).

Transfac database search revealed a potential AML1a binding site at position -32 in the 166 bp mouse BPI promoter, which was not included in the short 27 bp deletion variant. The activity of the 27 bp promoter was significantly reduced, as compared to the larger 166 bp promoter, when transiently transfected in both 15P-1 and MPRO.C1 cells, indicating an important and functional role for this AML-1 site in the transcriptional regulation of the endogenous expression of mouse BPI gene (**Paper III**). Of course, this is not a definitive answer if the mouse BPI promoter has functional binding site for AML-1 or not. First, the Transfac database can give false-positive results or can have missed an potential AML-1 site at another position within the mouse BPI promoter, because this program is based on PWM (position weight matrix). These PWMs are calculated from a set of experimentally defined transcription factor binding sequences and reflect binding specificity for the transcription factor [299]. Secondly, the potential binding site for AML-1 requires further analysis with other methods, including site-directed mutagenesis, and functional binding assays like EMSA or ChIP (as discussed in experimental considerations).

To further compare the mouse and human BPI promoter, we performed a phylogenetic footprinting. Phylogenetic footprinting is the identification of conserved regulatory elements by comparing genomic sequences of ortholog

genes [300]. This computational method is based on the hypothesis that the finding of conserved binding sites when aligning the regulatory sequences of orthologous with each other, increases the possibility that the binding sites are functional for the transcriptional regulation of the endogenous gene expression.

The gene for mouse BPI is located at chromosome 2 and shows a similar exon-intron organization as the gene for human BPI, which is located at chromosome 20. The mouse BPI gene and human BPI gene encode similar amino acid sequences. Encoded proteins have both antibacterial activity towards gram-negative bacteria and both proteins are, based on these criteria, defined as orthologs to each other (**Paper II**). Given the potential AML1 site in the mouse BPI promoter, it was of interest to determine whether a similar or conserved AML1 site was present in the human BPI promoter. We used the ConSite internet-based program [301] for the alignment of the promoters of human BPI gene and mouse BPI gene. The input promoter sequences we analyzed were the 166 bp long mouse BPI promoter fragment and the 222 bp long human BPI promoter fragment. We found that the potential AML1a site at position -32 in the mouse BPI promoter indeed is conserved in the human BPI promoter at position -142 as shown in **figure 6**. One has to remember that the numeration of the orthologous promoters in paper I and III are not directly comparable. The numeration in the mouse BPI promoter is relative to and upstream of the identified transcription start, while in the human BPI promoter the numeration is relative to the translation start (**Paper I and III**).

The human BPI promoter contains two AML1 sites, one at position -155 and one at position -142 and both are functional as judged by the performed *in vitro* experiments. AML-1 protein bound specifically to the AML1 probe (which contains both sites) as demonstrated by a supershift in EMSA (**Paper I**). The disrupted complex formation when both AML-1 sites are mutated in the unlabeled DNA probe in a competition experiment in EMSA was also in good correlation with the reduced promoter activity when both AML-1 sites are mutated in the 222 bp promoter fragment of human BPI (**Paper I**). Furthermore, deletion analysis of the human BPI promoter

showed reduced promoter activity of the 134 bp fragment as compared with the highest luciferase activity obtained with the 159 bp fragment (**Paper I**). This finding suggest that there is some important cis-element missing in the 134 bp promoter fragment, which is indeed included in the 159 bp fragment. This site is probably the conserved AML-1 site at position –142 and this, together with the results obtained of the EMSA, supports our hypothesis that the conserved AML-1 site is functional in the transcriptional regulation of the mouse BPI gene in the myeloid cell.

The phylogenetic footprinting analysis also indicated a conserved Sp1/Sp3 binding site, which was not found with the Transfac database program when analysing the promoter sequence of mouse BPI gene. This conserved Sp1/Sp3 site in the human BPI promoter is located at position –136 (relative to ATG) and in the mouse BPI promoter it is located at –26 (relative to TS) as shown in **figure 6**. For the mouse BPI promoter, the potential Sp1/Sp3 site at position –15, which was found with Transfac database and not with ConSite database, is like the potential Sp1/Sp3 site at position –26 included within the 27 bp deletion mutant. This latter indicates that both binding sites, respectively, can be responsible for the minimal promoter activity, as demonstrated by the luciferase reporter assays in 15P-1 and MPRO.C1 cells (**Paper III**). The finding that the Sp1/sp3 site at position –26, which is found to be functional in the human BPI promoter (**Paper I**), is conserved, makes the possibility higher that this site also is functional for the transcriptional regulation of the mouse BPI gene. Other conserved sites found by the combination of phylogenetic footprinting and Transfac database search, include USF, Lmo2, another AML-1 site, c-Rel and cap as represented in **figure 6**. If these sites have some functional importance in the myeloid-specific regulation of human-and mouse BPI gene has to be further investigated.

```

mouse BPI          TCTCAACAGGCTCGCGCGTGTGGCATGGGTGGGCGCGTGCACGTGCACAGCACATGCGC
human BPI          -----ACACGCATGCAT
                                * *****

mouse BPI          ACATGCCCATGCTCGCACAGACCTCTAGGCTCCACTGGGGCAGCCCCGGACTGGTCCCC
human BPI          ACATGGACATGCGAGC-----CTCCAGGCTGCACCT--TCTCCCTGCCTGTGGGGCCCT
*****          * * * * * * * * * * * * * * * * * * * * * * * * * * * *

mouse BPI          AACGTTGATGGGGAACCGCAGCTGCCCTCCC-----
human BPI          AACCAATGAAAACACAGCGGCCCTCCCTCTTCCCACCTCACCAGGTTCCCTCCT
***          * * * * * * * * * * * * * * * * * * * * * * * * * * * *

mouse BPI          -----
human BPI          CCTTCCACATTTACTACTGACTTTGCATTTCCCAGCGACTCTTTTATAGTCCCTGGTTC
                                ↑
                                TS (human)

mouse BPI          -----CCTCCGCCCCACGGCTGCCTTCC
human BPI          AACCTCAAGGCTTGAGGTTTGGCAGCTCTGGAGG
                                * * * * *
                                TS (mouse)

```

Figure 6. Conserved transcription factor binding sites within the promoters of human - and mouse BPI using phylogenetic footprinting and Transfac database search.

A.2. Is the transcriptional regulation of the BPI genes comparable to other neutrophil granule protein genes? (Paper I, II, and III)

When we started our investigation of the transcriptional regulation of the human BPI gene in myeloid cells, two observations from the literature made us speculate that human BPI has different transcriptional regulation than other azurophil granule proteins. First, newborn neutrophils are shown to have three-to four-fold less intracellular BPI content than adult neutrophils, while other azurophil granule proteins, α -defensins and myeloperoxidase, are present in identical amounts in neutrophils of newborns and adults [227]. Secondly, the neutrophils of patients with Specific Granule Deficiency (SGD) lack the azurophil granule proteins BPI and α -defensins, while the azurophil granule protein myeloperoxidase is not affected [60]. In the case of SGD, it is therefore suggested that the transcriptional regulation of BPI is similar to that of the specific granule proteins lactoferrin and collagenase, and might be also similar to that of the α -defensins, but differs from transcriptional control of the azurophil granule protein myeloperoxidase. SGD is a very rare disease, only five cases are known worldwide, and some of the SGD patients show homozygous inactivating mutations of the C/EBP ϵ gene, from which is known that the encoded wild-type C/EBP ϵ

protein is important in the regulation of the lactoferrin and collagenase expression [90, 127]. C/EBP ϵ -deficient mice show functional defects of neutrophils very much alike those defects seen in SGD patients. Thus data strongly suggest that C/EBP ϵ is important for the expression of both BPI and α -defensins in myeloid cells. However, at that time Gombart *et al* published its review, indicating that C/EBP ϵ is involved in the molecular basis of SGD, α -defensins and BPI were not known to be present in mouse neutrophils [60, 206], indicating that a comparison between human and mice was difficult to make. Now, we have demonstrated the expression of BPI mRNA in mouse bone marrow cells by using real time RT-PCR and detected BPI protein by immunochemistry (**Paper II**).

Eisenhauer *et al* did not detect α -defensins in mouse myeloid cells using Northern Blot. However, using more sensitive techniques like real time RT-PCR, it is may be possible to detect low expression levels of α -defensins in mouse neutrophils too.

The lower expression level of BPI mRNA in mouse bone marrow as compared to human bone marrow can be due to lack of a potential C/EBP site as already discussed above, but also the potential 'very' low expression of α -defensins in mouse neutrophils can may be due to this lack of potential C/EBP-site in its promoter.

The human BPI –and α -defensin promoters do contain functional C/EBP sites. C/EBP β and C/EBP ϵ bind the human BPI promoter *in vivo* [298] and the ectopic overexpression of C/EBP α induces the human BPI promoter in a direct or indirect fashion as it was demonstrated *in vitro* (**Paper I**). The human α -defensin promoters bind C/EBP α and this transcription factor plays an important role in the regulation of α -defensins gene expression in immature myeloid cells [82].

Further, it is demonstrated that BPI and α -defensins are synthesized later than the other azurophil granule proteins, such as MPO (myeloperoxidase), PR3 (proteinase 3) and NE (neutrophil elastase) during the promyelocyte stage of myelopoiesis in the human bone marrow [302, 303]. Both human α -defensins and human BPI, contain potential CDP-sites in their promoters,

which can play a role in the later expression of both proteins during the promyelocyte stage of myelopoiesis, knowing that CDP is a repressor of gene expression, and that the repressor-activity of CDP is downregulated upon differentiation of myeloid cells [82-85, 298]. CDP represses the expression of the human lactoferrin gene but as myeloid cells differentiate beyond the promyelocyte stage, the CDPs repressor-activity is downregulated which results in the expression of the lactoferrin gene [86, 302]. If the transcriptional regulation of human BPI is similar to that of human lactoferrin, as could be suggested from the observation in SGD patients, CDP could play an important role in the regulation of human BPI gene. However, we have so far not been able to demonstrate a functional role for CDP in the regulation of human BPI and there are no data available from the literature supporting a role for CDP in the expression of α -defensin genes during myelopoiesis. In addition, no conserved CDP site was found when aligning the human and mouse promoters in the phylogenetic footprinting analysis, so the role of CDP in the regulation of both BPI promoters is not clear. CDP is also known to negatively regulate the C/EBP ϵ promoter activity [304], so hypothetically CDP can also indirectly regulate the expression of the human BPI gene via repression of C/EBP ϵ .

Are the transcription factors PU.1, AML1 and Sp3 responsible for the different expression profile of BPI as compared to the other azurophil granule proteins MPO, PR3 and NE?

PU.1 regulates almost every myeloid-specific gene [25], including the human PR3 gene [74] and the MPO gene [70]. The enhancers of both human and mouse MPO contain also functional AML1 sites [45, 64, 72], but it is not demonstrated that AML1 regulates the other azurophil granule proteins like proteinase 3 or the α -defensins. The promoters of human α -defensins contain two potential AML1 sites, which are not found in the PR3 promoter [74, 82]. Therefore, the transcription factors PU.1 and AML1 do not act alone or separately, but most likely bind with other regulatory factors to make the expression profile of human BPI different as compared with the other azurophil granule proteins PR3, NE or MPO.

It is shown for the M-CSF receptor, for example, that its promoter contains three adjacent and functional binding sites for C/EBP α , AML1, and PU.1 and that AML1 physically interact with PU.1 and C/EBP α to activate the M-CSF receptor promoter in a synergistic fashion [136]. However, we could not find a direct binding of C/EBP α to the human BPI promoter [298], but ectopic expression of C/EBP α in HeLa cells was able to strongly activate the human BPI promoter as compared to the ectopic expression of C/EBP ϵ . We can only speculate that the ectopic expression of C/EBP α is able to induce the expression of other transcription factors or can interact with other factors, such as Sp1/Sp3, which are endogenously expressed in HeLa cells [305, 306], and in this way induce the human BPI promoter. Besides direct binding of AML1 and PU.1, we found that Sp3 also binds specifically to the human BPI promoter, and hereby, we demonstrate that the human BPI gene is the first myeloid-specific gene that is positively regulated by a direct and functional binding of Sp3.

Sp3 belongs, together with Sp1, to the Sp family of zinc finger DNA-binding proteins and shows more than 90% identity to Sp1 in the zinc finger DNA-binding region [142, 143]. Sp1 and Sp3 are both ubiquitously expressed, and they compete for binding to GC boxes in several cell types [142]. Sp3 can not only work as an activator, but can also work as a repressor [307]. Recently, it was shown that Sp3 is a target for sumoylation which is essential for its repressive activity [154]. We can only speculate on that during early myelopoiesis, the sumoylated form of Sp3 represses the BPI expression and later it can in its unsumoylated form activate the BPI gene expression.

B. A mouse antibacterial ortholog to human BPI (Paper II)

There are numerous of genes that have been conserved through evolution and their protein products can be found to be expressed in many different species, like human and mice. Genes or proteins from different species that share a common ancestor and have the similar functions, are defined to be

orthologs. In **paper II**, we identified a mouse ortholog to human BPI, which was similar in structure and function and, like human BPI, is found to be expressed in testis and in bone marrow cells.

We cloned a mouse BPI cDNA with a predicted molecular weight of 53 kDa and its predicted amino acid sequence was 53% identical and 71% similar to the amino acid sequence of human BPI. The identical or conserved amino acids, include the cysteines at position 132, 135, and 175 (as shown in figure 1 in paper II) and which are like in the human BPI sequence, located in the N-terminal half of the protein [217]. The cysteine residues at position 135 and 175 were previously demonstrated to play essential roles in the stability and function of the human BPI protein [308, 309], and are also shown to be conserved in the other related proteins, including LBP, CETP and PLTP, but not the cysteine residue at position 132 [309].

The three-dimensional (3D) - structure of the human BPI protein shows an unusual 'boomerang' structure (as shown in figure 2 in Paper II) formed by two 'quite' similar domains, as it was determined by Beamer *et al* [214]. Each domain contains a 'barrel' formed by two α -helices and a highly twisted antiparallel β -sheet. In the center of the protein, the two barrels are connected by a smaller antiparallel β -sheet, which consist of a proline rich sequence [214, 238, 310], which is also conserved between human BPI and the predicted mouse BPI (as shown with a line in figure 1 in paper II). A disulphide bridge that anchors the β -sheet to one of the α -helices in the N-terminal domain of the human BPI protein is formed by the two conserved cysteines at position 135 and 175 and are suggested to play also a role in the structure/stability and eventually similar function of the cloned mouse BPI. Based on the knowledge that the N-terminal domain is responsible for the bactericidal, LPS-binding, and LPS-neutralizing activity of human BPI [311, 312] and the conserved cysteine residues, which play a role in this biological activity [308, 309], we hypothesized that the cloned mouse BPI has similar functions as the human BPI protein. Therefore, we stably expressed recombinant human- or mouse proteins in HEK293 cells. These cells have no cytoplasmic organelles and we supposed that they should secrete their products into the medium. This conditioned medium was harvested and

analyzed for antibacterial activity toward a gram-negative bacteria, the *E. coli* strain J5 [313]. We found that the antibacterial activity against *E. coli* strain J5 of the recombinant mouse BPI was similar to that of recombinant human BPI, suggesting that mouse BPI has similar function against gram-negative bacteria as human BPI. The intact gram-negative bacteria, *E. coli* strain J5, as used in this *in vitro* assay, is a strain bearing short-chain lipopolysaccharide (LPS) in its outer membrane and is defined as a rough strain of *E. coli*. It is previously demonstrated that rough strains of *E. coli* are more sensitive to BPI than smooth strains of *E. coli* that produce LPS with varied chain lengths [314]. These smooth strains or also called wild-type strains, and are shown to modify the average length of the polysaccharide chain in response to changes in growth medium [315]. Therefore, although the use of the rough strain *E. coli* J5 in our *in vitro* bacterial killing assay gives us an answer whether mouse BPI show antibacterial activity. It does not tell whether the antibacterial activity is equally effective against other bacteria strains.

The polyclonal antibodies against our cloned mouse BPI, which were successfully used in the immunocytochemistry assay, did not work in assays like Western blot or in our bacterial killing assay. For this reason, it was impossible to analyze the expression/synthesis of endogenous mouse BPI at the protein level in mouse cell lines of interest. On the other hand, the mouse promyelocytic MPRO.C1 cell line, the mouse Sertoli TM4- and 15P-1 cell lines were analysed by real time RT-PCR and were found to express endogenous mouse BPI mRNA.

Based on the finding that mRNA of mouse BPI and human BPI was not only detected in bone marrow and promyelocytic cell lines, but also in tissues like testis and epididymis, we were interested in other antimicrobial proteins and peptides found in the tissues of the male reproductive organ. Indeed, one study demonstrate the existence of a number of mRNA transcripts of β -defensins with specific expression in distinct regions of the mouse epididymis, suggesting that these proteins play a role either in host defense or in other functions in this organ. The epididymis is a tubular male reproductive structure that lies on and around each testicle, connecting it

with the vas deferens [316] and is known to play an important role in the maturation of sperm, which after their production in testis, pass through the epididymis [317]. Another study showed that the epididymis-specific β -defensin, which has an ortholog in humans [318], have antimicrobial activity similar to that of other β -defensins [319], but that β -defensins also play also a role in the sperm maturation [320]. Human epididymis also seems to have high protein levels of hCAP-18 [321], known as the only human cathelicidin, first isolated in the specific granules of neutrophils [322]. The hCAP-18 is attached to the spermatozoa and is suggested to play a role in antimicrobial defense during human reproduction [323]. An immunocytochemistry assay indicated that a protein, called SOB3, is located in the acrosome of human spermatozoa and seems to play a role when the spermatozoa will pass through the zona pellucida during the fertilization of the oocyte [324]. Based on the alternative functions of these proteins found in the male reproductive organ, we can speculate that mouse - and human BPI might also have other functions than antimicrobial activity.

C. The Single Nucleotide Polymorphism (SNP) in the proteinase 3 promoter (Paper IV)

Genetic variation or polymorphisms with functional consequences can occur in the coding DNA (exonic sequence) or in noncoding, regulatory DNA (promoter-or enhancer sequence). Functional polymorphisms in the coding sequence of a gene gives rise to changes in amino acid sequence of the encoded protein, while functional polymorphisms in the regulatory sequences can change the mRNA levels. Most genetic variations exist as a single base change in the DNA sequence, known as Single Nucleotide Polymorphism (SNP), and this occurs approximately once every 1000 nucleotides [325]. Sometimes SNPs are associated with human diseases. We hypothesized that the -564 A/G SNP in the promoter region of proteinase 3, which introduces a new potential Sp1 binding site, may be responsible for the observed up-regulated proteinase 3 membrane expression in myeloid cell

of patients with Wegener's Granulomatosis (WG). Our hypothesis was based on the finding that the -564 A/G SNP was over-represented in patients with WG as compared to healthy controls [326]. Similarly, a common polymorphism (-463 G/A) in the myeloperoxidase (MPO) promoter, which creates an additional Sp1 site, resulted in a 25-fold increase of transcriptional activity [327] and this SNP might be associated with WG [328], or not [329]. To test this hypothesis, we transiently transfected promyelocytic HL60 and NB4 cells, monocytic U937 cells, and cervix carcinoma HeLa cells with three variants of the proteinase 3 promoter (-564 A/G; -621 A/G; and wild-type), as represented in figure 1 in **paper IV**, and analyzed promoter activity. We found highest promoter activity in HL60 cells, which also was the cell line showing highest levels of endogenous gene expression. No significant promoter activity was seen in the HeLa cells, demonstrating that the analyzed proteinase 3 promoter shows a myeloid-specific activity. However, within each cell line, our data fail to reveal any significant differences in promoter activity among the three variants, thus strongly arguing against our hypothesis. A possible explanation to the absence of any effect on transcription from the new Sp1 site is that the potential Sp1 site at position -564 might be too far separated from the TATA-box to give an induction of the proteinase 3 promoter activity.

In the case of the polymorphism of the MPO promoter, as mentioned above, we speculate that the additional Sp1 site is functional, because it is located at close distance to the alternative transcription start site P2 in this MPO promoter [330]. Although it is shown in the study of Lin *et al* that the wild-type MPO gene is transcribed *in vivo* primarily using the P1 promoter and that low levels of transcription occurs at the alternative P2 site, we can not exclude that the additional Sp1 site near this P2 site in the mutant MPO promoter is able to increase the level of transcription. A previous study showed a functional and important Sp1 site near the P1 transcription start site in the wild-type MPO promoter, indicating again that close distance of Sp1 sites to the transcription start site is essential for increase of promoter activity [63].

In conclusion, we demonstrated that the –564 A/G SNP in the proteinase 3 promoter is not the answer why resting neutrophils or monocytes of WG patients have increased proteinase 3 expression.

V. Conclusions

- The BPI mRNA expression during myelopoiesis is regulated by the transcription factors AML-1, PU.1 and Sp3. The reason that BPI is later expressed than other azurophil granule proteins, like myeloperoxidase (MPO), proteinase 3 (Pr3) and neutrophil elastase (NE) is still unknown, but we can speculate, based on our results in this study, that the transcription factor Sp3 can play an important role in the unique expression profile of BPI during myelopoiesis. BPI is the first myeloid-specific gene shown to be regulated by Sp3.

- Human - and mouse BPI are structurally and functionally conserved and are defined to be orthologs to each other. Mouse BPI mRNA was detected in testis, epididymis, bone marrow cells and Sertoli-and promyelocytic cell lines. Mouse BPI mRNA expression was induced when Sertoli cells 15P-1 and the promyelocytic MPRO.C1 cells were stimulated with ATRA. In contrast to human BPI, the ATRA- induction of mouse BPI mRNA expression seems, at least partly, to be independent of *de novo* protein synthesis, indicating direct effects of ATRA on the mouse BPI promoter.

- Mouse bone marrow cells express much lower levels of BPI mRNA as compared to human bone marrow cells. We found that the proximal mouse BPI promoter lack a potential C/EBP binding site, which can be

responsible for the lower expression of BPI mRNA in mouse bone marrow cells. Furthermore, we found a conserved, but potential AML-1 binding site in the promoters of human -and mouse BPI gene. However, further studies are necessary to demonstrate the functionality of the AML-1 site.

- The -564 A/G Single Nucleotide Polymorphism (SNP), which introduces an potential Sp1 binding site in the promoter of proteinase 3 gene, is not responsible for the increased expression of proteinase 3 in myeloid cells of patients with Wegener's Granulomatosis. Further investigations must be done to understand the molecular mechanisms behind the increased proteinase 3 expression in myeloid cells or other risk factors in the pathogenesis of Wegener's Granulomatosis.

Populärvetenskaplig sammanfattning på Svenska (Samenvatting in het Zweeds)

Våra vita blodceller bildas i benmärgen och när de mognat färdigt hamnar de i blodcirkulationen. Det finns olika typer av vita blodceller och varje typ har sin egen funktion. En speciell typ av vit blodcell, nämligen den myeloida vita blodcellen (neutrofilen), spelar en mycket viktig roll i kroppens första försvar mot invaderande bakterier. När bakterier kommer in i kroppen någonstans, lämnar de myeloida vita blodcellerna blodcirkulationen och vandrar till det stället och dödar de invaderande bakterierna. Avdödning av bakterier sker med hjälp av bakteriedödande proteiner som cellerna själva producerar och förvarar i små behållare, sk granula, inuti i cellerna. Livslängden för mogna neutrofiler är begränsad till några dagar och behöver därför hela tiden ersättas av nya celler från benmärgen. Mognadsprocessen av neutrofiler i benmärgen sker i ett antal på varandra följande steg, varvid olika sorters bakteriedödande proteiner bildas och lagras i granula. Beroende på när proteinerna bildas under mognadsprocessen, hamnar de i olika sorter granula i neutrofilen.

Proteiner bildas med hjälp av ärftlig information som finns i våra gener. Gener är uppbyggda av DNA och finns i cellens kärna, vilken är avgränsad från resterande delen av cellen, cytoplasman. När en gen uttrycks betyder det att den läses av på ett sådant sätt att den blir översatt till det protein genen innehåller information om. Instruktion om vilka proteiner som ska tillverkas, i vilka mängder och på vilka tidpunkter under utmognaden, är alltså förvarad i våra gener.

När en gen uttrycks bildas först en slags kopia av den. Denna kopia, som kallas mRNA, transporteras ut ur kärnan till cytoplasman där den fungerar som mall för de proteiner som skall tillverkas. Bildandet av mRNA styrs med hjälp av så kallade transkriptionsfaktorer. Transkriptionsfaktorer är proteiner som binder till vissa delar av reglerande DNA i gener och kan därmed bestämma om genen ifråga skall uttryckas eller inte. Beroende på vilka, och på vilket sätt, transkriptionsfaktorer binder till DNA, bildas antingen många eller få mRNA-kopior, eller ibland inga mRNA-kopior alls. Exakt hur och när transkriptionsfaktorer binder till DNA för att skapa mRNA-kopior är en

komplex process och mycket forskning pågår för att förstå detta helt. I min avhandling har jag undersökt hur och när mRNA-kopior av vissa gener bildas under mognadsprocessen av neutrofiler.

I **studie I** har vi identifierat några transkriptionsfaktorer som spelar en viktig roll i bildningen av mRNA-kopior som leder till produktionen av det bakteriedödande proteinet ”bactericidal permeability increasing protein” (BPI) under mognadsprocessen av neutrofiler. Resultaten har gett oss ökad insikt i och förståelse för varför BPI inte bildas vid vissa sjukdomar.

I **studie II** har vi upptäckt att BPI finns inte bara i myeloida vita blodceller hos människa, utan att också i blodceller från mus bildas små mängder av BPI-proteinet. BPI hos mus är inte tidigare upptäckt av andra forskare. Vi fann också att mRNA-kopior av BPI bildas i vissa celler av manliga könsorgan i både människa och mus.

I **studie III** var jag nyfiken på varför det bildas mycket mindre mRNA-kopior av BPI genen i benmärgen hos mus, i jämförelse med människa. Därför ville jag undersöka om vissa transkriptionsfaktorer som spelar en viktig roll i uttrycket av BPI genen hos människa är viktiga också för uttrycket av BPI-mRNA hos mus. Tyvärr har jag inte hunnit ända fram i detta delprojekt, men mina resultat antyder ändå att BPI-genen i mus saknar de inbindningsställen för en viss typ av transkriptionsfaktor. Denna transkriptionsfaktor är viktig för bildningen av stora mängder av BPI proteinet i människans vita blodceller och eftersom motsvarande faktor hos musen inte kan verka på BPI-genen där, skulle det kunna förklara varför BPI-nivåerna är låga i myeloida celler hos mus.

I **studie IV** undersökte jag hur det reglerande DNA i en annan gen, nämligen genen som kodar för proteinas 3, är uppbyggd för att bättre kunna förstå varför myeloida vita blodceller av patienter med en sjukdom som kallas Wegener’s Granulomatosis (WG) bildar större mängder av proteinas 3-proteinet, i jämförelse med friska personer. Överproduktionen av proteinas 3 kan kanske vara en bidragande orsak till att dessa patienter utvecklar farliga inflammationer i små blodkärl. Många patienter med WG har en särskild variant av det reglerande DNA i proteinas 3-genen. Jag hypotetiserade att denna variant orsakar att fel transkriptionsfaktor binder in, vilket i sin tur leder till produktion av stora mängder proteinas 3-protein. Men min hypotes visade sig vara fel. Mer

forskning krävs alltså för att undersöka orsaken till överproduktionen av proteinas 3 i WG patienter.

Samenvatting in het Vlaams

(Populärwetenskaplig sammanfattning på flamländska)

Onze witte bloedcellen worden gevormd in het beenmerg en wanneer ze rijp zijn komen ze in de bloedcirculatie terecht. Er zijn verschillende soorten witte bloedcellen, die elk hun eigen functie uitoefenen in het immuunsysteem van ons lichaam. Een bepaalde soort witte bloedcel, namelijk de myeloïde witte bloedcel (de neutrofiel), speelt een belangrijke rol in de eerste verdediging tegen binnengedrongen bacteriën. Tijdens een ontstekingsreactie, kan de myeloïde witte bloedcel de bloedcirculatie verlaten door de wand van de allerkleinste bloedvaten om in de ontstoken weefsels de binnengedrongen bacteriën te vernietigen. Het vernietigen van bacteriën gebeurt met de hulp van bacteriedodende eiwitten die geproduceerd worden door de cel zelf en die als het ware bewaard worden in blaasjes (granules) binnenin de neutrofiel. De levensduur van de rijpe neutrofiel is beperkt tot enkele dagen en vandaar dat ze voortdurend moet vervangen worden door nieuwe cellen vanuit het beenmerg. Het rijpingsproces van de neutrofielen in het beenmerg verloopt in een aantal opeenvolgende herkenbare stappen, waarbij verschillende soorten bacteriedodende eiwitten worden aangemaakt die bewaard worden in de granules. Afhankelijk van het tijdstip wanneer de eiwitten worden aangemaakt tijdens het rijpingsproces komen ze terecht in verschillende soorten granules binnenin de neutrofiel.

Eiwitten worden aangemaakt aan de hand van erfelijke informatie die vastligt in onze genen. Onze genen zijn opgebouwd uit DNA en bevinden zich in de kern van de cel, afgezonderd van het grootste resterende deel van de cel, het cytoplasma. Wanneer een gen tot expressie komt wil dit zeggen dat een gen wordt afgelezen zodanig dat het kan vertaald worden tot de aanmaak van

eiwitten waarvan het gen informatie bevat. De instructies hoe eiwitten worden aangemaakt, in welke hoeveelheden en op welke tijdstippen van het rijpingsproces ligt allemaal vast in onze genen. Wanneer een gen tot expressie komt, wordt er eerst van het DNA een soort kopie gemaakt. Deze kopie, dat men mRNA noemt, wordt dan getransporteerd van de celkern naar het cytoplasma waar de eiwitten daadwerkelijk worden aangemaakt met de hulp van de instructies die deze mRNA-kopie bevat.

Het maken van mRNA-kopies gebeurt met de hulp van zogenaamde transcriptiefactoren. Transcriptiefactoren zijn eiwitten die zich met bepaalde delen van het regulerende DNA binden en op deze manier beslissen of het gen in kwestie tot expressie zal komen of niet. Afhankelijk van de manier waarop en welke transcriptiefactoren het regulerende DNA binden, worden er veel of weinig mRNA-kopies aangemaakt, of soms worden er zelfs geen mRNA-kopies aangemaakt. Het hele proces van hoe en wanneer transcriptiefactoren binden met het regulerende DNA om mRNA-kopies aan te maken is ingewikkeld en er worden heel veel studies gedaan om dit proces beter te begrijpen.

In mijn thesis heb ik me vooral geconcentreerd op hoe en wanneer mRNA-kopies van bepaalde genen worden aangemaakt tijdens het rijpingsproces van de neutrofiel.

In **studie I**, hebben we een aantal transcriptiefactoren geïdentificeerd die verantwoordelijk zijn voor het aanmaken van RNA-kopies die in hun beurt tot de aanmaak van het bacteriedodende eiwit 'Bactericidal/Permeability-Increasing protein' (BPI) leiden tijdens het rijpingsproces van de neutrofiel. De identificatie van deze transcriptiefactoren kan ons meer inzicht geven waarom in bepaalde ziektes het eiwit BPI niet wordt aangemaakt.

In **studie II**, ontdekten we dat het eiwit BPI niet alleen wordt aangemaakt in de myeloïde witte bloedcellen van de mens, maar dat zelfs muizen het eiwit BPI in kleinere hoeveelheden aanmaken in hun myeloïde witte bloedcellen. BPI in muizen was voorheen nog nooit aangetoond door andere wetenschappers. We zagen ook dat mRNA-kopies van het BPI gen worden aangemaakt in bepaalde cellen van het mannelijk geslachtsorgaan van zowel muis als mens.

In **studie III**, was ik nieuwsgierig waarom dat de myeloïde witte bloedcellen van de muis veel minder mRNA-kopies van het BPI gen aanmaken in vergelijking tot de mens. Daarom wilde ik nagaan of de transcriptiefactoren die verantwoordelijk zijn voor de aanmaak van mRNA-kopies van het BPI gen in de cellen van de mens ook belangrijk zijn in de cellen van de muis. Helaas was de tijd tekort om deze studie af te maken, maar mijn resultaten wijzen erop dat het BPI gen in muizen een bindingplaats voor een bepaald type van transcriptiefactor mist. Deze transcriptiefactor is belangrijk voor de aanmaak van grote hoeveelheden van het BPI eiwit in de myeloïde witte bloedcellen van de mens en omdat de muis dat bepaald type van transcriptiefactor mist om BPI mRNA-kopies aan te maken, kan dit een mogelijke verklaring zijn waarom BPI in veel kleinere hoeveelheden wordt aangemaakt in de muis.

In **studie IV**, bestudeerde ik hoe het regulerende DNA van een ander gen, namelijk het gen dat de informatie bevat om het eiwit 'proteinase 3' aan te maken, is opgebouwd om te kunnen verstaan waarom de myeloïde witte bloedcellen van patiënten met de ziekte Wegener's Granulomatosis (WG) grotere hoeveelheden van dit eiwit proteinase 3 aanmaken in vergelijking tot gezonde mensen. Deze overproductie van het eiwit proteinase 3 is misschien de oorzaak dat deze patiënten ernstige ontstekingen krijgen in de allerkleinste bloedvaten. Vele patiënten met WG hebben een speciale opbouw van het regulerende DNA in het proteinase 3 gen. Ik ging er vanuit dat deze speciale opbouw van het regulerende DNA ervoor zorgde dat een verkeerde transcriptiefactor kan binden met dit DNA en er dus zo zou voor kunnen zorgen dat er te grote hoeveelheden van dit proteinase 3 eiwit worden aangemaakt. Ik kwam tot de waarneming dat dit niet zo bleek te zijn. Dus er moet meer onderzoek worden verricht om de oorzaak van deze overproductie van het eiwit proteinase 3 in WG patiënten beter te begrijpen.

Acknowledgements

Äntligen är det dags att skriva denna sidan som jag har väntat på så länge, inte bara för att jag tycker det är så viktigt att tacka alla som var mer eller mindre, på direkt eller odirekt sätt, involverat i mitt arbete, men också för att det betyder att jag har nästan nått det sista steget av min forskningsutbildning. Det var en tuff väg att gå, mina damer och herrar, men det har varit så lärorikt!
TACK SKA NI ALLA HA!!!

För att ni förmodligen inte vet varför jag precis har er att tacka för har jag skrivit upp det för er alla och så vill jag framförallt börja tacka:

Min handledare **Urban Gullberg** för att du har givit mig möjligheter och chanser att upptäcka en komplex värld av transkriptionellt reglering, uppreglering och ektopiskt överuttryck i myeloida celler. Jag beundrar din talang att förklara komplexa molekylära fakta i enkla ord och på ett förståeligt sätt och på så sätt lärde jag mig mycket av din pedagogik. TACK!

Andreas Lennartsson, min 'andra' handledare, arbetskamrat och mentor som har stöttat och uppmuntrat mig under hela min doktorandtid. Jag lärde mig att det också finns ett optimistiskt sätt att titta på livet och forskning. Tack för att du lärde mig maxipreppa och köra luciferase assays, de här metoderna har varit av stor nytta under min doktorandtid! Och naturligtvis stort tack för alla lärorika diskussioner inom BPI-projektet, jag uppskattade det initiativet för de mötena jättemycket!

Karina Vidovic, för att du lärde mig att extrahera totalt RNA på Swengelska och för alla andra 'never-failing' protocols. Jag är imponerad av ditt engagemang i UG-gruppen och jag tackar dig mycket för alla de roliga stunder under pipetterade och flyttande!

May-Louise Andersson, för att du ville tro på mig, ett stöd som jag behövde då och då, och för att du alltid har haft lite tid över för att lyssna på mig och även för att du har hjälpt till med det ekonomiska och allt annat pappersjobb. Du är en mycket varm och trevlig människa!

Ellinor Johnsson, för allt snack om kärleken och livet. Jag gillar ditt sätt hur du underhåller oss under fikatid och det gav 'oss' många riktiga bra och mysiga stunder! Tack för allt stöd och skratt under tiden av bedövning och i vaken tillstånd!

Alla trevliga (nuvarande och tidigare) personer i UG-gruppen:

Susanna Obad, för bra Northern blot tips; din Bob Dylan Skivan (!), och dina två maxipreppar med pGL3 Basic och pGL3 promoter som du spontant gav till mina sista luciferase körningar! **Emelie Svensson**, för din kikärtgergryta-recept med lågglykemisk index och din svenska humor, **Malin Ageberg**, för att du lärde mig att laga sushi och att transfektera 293GPG celler, det ena gick lite

bättre än det andra förstås, **Magnus Nyhlén**, för alla dina komplimanger att jag var din bästa handledare, jag tror dig fortfarande inte ☺, men även om DU inte tror det har jag haft det JÄTTEKUL med dig! ☺ (Att skratta är förmodligen nödvändigt för bra forskning), **Kristina Drott**, för att du är personligt och professionellt samtidigt (och för att du gillar Patti Smith), **Helena Svedberg**, för dina Sydsvenskan-annonser som hjälpte mig att leta efter bostad i Lund; **Tove Ullmark** och **My Truong**, för vänskapen i och utanför labbet, **Karin Arvidsson**, för att du gjorde mig till 'Ronja Rövardotter' på Julfesten år 2002!☺, **Christos Gekas**, för livsviktigt råd, **Anders Lindmark**, för HemBerit och **Daniel Garwicz**, för bra tips till min ramberättelse.

Alla trevliga (nuvarande och tidigare) personer i IO-gruppen:

Inge Olsson, för att du ibland ställde annorlunda, men bra frågor som fick mig att tänka lite extra; **André Olsson**, för att du lärde mig att göra diagram i excel-programmet, de finns nu i arbete IV (finns bara 1 figur, du kan inte missa den) och för annan datorhjälp, **Ann-Maj Persson**, för alla trevliga samtal och uppmuntrade ord i cellodlingsrummet, **Ellinor Bulöw** och familj, för att ni hjälpte mig att komma hem med alla mina ny köpta IKEA-grejer, **Hanna Rosén** och **Sofia Rondin-Lindberg**, för att jag aldrig ska glömma hur roligt vi hade det på vårt utflykt till konferensen i Köpenhamn ☺ !, **Marta Salles Aromir**, for all the fun we had in-and outside the lab during your stay in Sweden and of course because you learnt me to make a Spanish Tortilla, **Ying Gao**, for your Chinese way of being and your kindness, **Sofia Jönsson**, för att du fixade maten till min inflyttningsfest på Kämnärsvägen, **Markus Hansson** och **Linda Källqvist**, för trevlig sällskap på min sista Julfest på avdelningen.

Alla trevliga (nuvarande och tidigare) personer på njurlabbet:

Thomas Hellmark, för ett framgångsrik samarbete och hjälp i proteinase 3-projektet, **Sophie Ohlsson**, för att real time PCR utan dig hade varit omöjligt, **Åsa Pettersson**, för tiden du spenderade för att visa mig hur Optiprep fungerar, efteråt visade sig att det inte var så självklart när jag själv försökte att separera monocyterna från lymfocyterna i det perifera blodet, **Lena Gunnarsson**, **Susanne Lahdenperá**, **Nermina Jaganjac**, **Mohammed Abdgawad**, och **Nana & Ole Torffvit**, för trevliga fikastunder och korridormöten, **Mårten Segelmark**, för att vi nästan hade haft ett samarbete om BPI och proteinase 3 hade låtit sig uppregleras, men tyvärr!

Alle trevliga (nuvarande och tidigare) medlemmar i TO-gruppen:

Tor Olofsson, för att du gillar Belgien och sin gastronomi, **Bodil Rosberg**, för att du vet allt om tekniska problem på labbet, **Stefan Sköld**, för att du har en snygg bil, **Louise Edvardsson**, för en bra banan-chokladkaka, **Josefina Dykes**, för ditt leende och positivism som kunde göra en tråkig dag på labbet lite lättare, **Britt Thuresson**, för intressante diskussioner om RNA och 5'RACE-tekniken, **Lennart Zeberg**, för ditt ro och intressanta diagnoser, och för att du också alltid jobbar under helgen☺.

Monica, för att det var nästan omöjligt att städa vårt skrivrum och ändå försökte (Förlåt mig, Andreas) ☺

Lars och Levente, för att installera alla viktiga program på min dator och hur ni lärde mig att använda de.

On the other side of the road:

Heike & Knut Kotarsky för att ni är så snäll och omtänksam, **Ann-Lie Ståhl**, **Fariba Vaziri-Sani**, **Ann-Charlotte Kristoffersson** och andra personer i **Diana Karpmans** grupp, för att vi haft det så himla roligt på Blood & Defense konferens i Gilleleje (Danmark), **Vera Noskova**, for your Oriflame handcreme, (it was very popular in our UG-group) and your happiness, **Barbara Bottalico**, for your sunshine during the cold Swedish winter och **Stefan Hansson och hans grupp**, för varma hälsningar i korridoren.

Outside C14:

Bo Åkerström, för att du hjälpte mig på väg dit, **Peter Osmark**, för din danska humor, din uppmuntring och för din ex-handledning i molekylär biologi, **Maria Allhorn**, för din polska humor och din uppmuntring, **Karin Berger**, för att jag blev inspirerad av ditt 'Acknowledgements' och din fantastiska humor, **Victoria Rydengård** och **Mina Davoudi**, för alla trevliga lunchdates vi hade på Olles Fik (inklusive de andra medlemmarna i lunchklubben förstås☺), **Ulrika Mårtensson**, utan gympande på Gerdahallen och utan dig hade jag aldrig orkat med, att röra på sig var mycket viktigt! Tack ska du ha för alla trevliga gympa-och bastu-stunder! Tack också till **Jill Storry**, **Bahram Hosseini-Maaf** och **Elisabeth Sjöberg-Wester**, för era besök till vårt RNA-labb och **Lena Wester**, för en trevlig bilutflykt i Skåne.

Outside BMC:

Teres, för att du lärde mig mina första ord på svenska och för vår vänskap som var av oerhört vikt under de 5 åren i Lund, **Hans**, **Elizabeth**, **Ester**, **Sofia**, **Erik och alla andra i Pettersson familjen**, för att jag alltid varit välkommen hos er; **Maj-Linda**, **Åsa**, **Katrin**, **Sofia**, **Lasse**, för vänskap, stöd, roliga fester och trevliga & goda middagar; och **Jerry**, för att du visade mig ett annat Sverige i Göteborg.

Outside the country of Sweden:

Veerle, for very important and sometimes also extremely funny telephone conversations; **An & Liesbeth**, for the nice hospitality when I was on holiday in Belgium, **Florian**, for the exchange of music between Germany and Sweden, **Bahram Nikpur**, for unexpected messages on my answeringmachine; niet te vergeten ook: **vrienden van Kruike** en **Johan & Jan**; and my sister **Ilse** and her boyfriend **Marc**, for helping me install my pentryroom at Kämnärsvägen and other sweet things.

And last but of course not least, I am forever thankful to **my parents**, **Garry** en **Marie-Thérèse (vake en moeke)**, bedankt voor jullie ongelooflijk geduld gedurende al die jaren en de enorme onschatbare steun zowel thuis als aan de telefoon! Zonder jullie had ik dit nooit klaargespeeld!

References

1. Hoffbrand AV, P.J., Moss PAH (2001) *Essential Haematology*. Blackwell Publishing.
2. Howard MR, H.P. (1997) *Haematology*. Churchill Livingstone.
3. Roitt Ivan, B.J., Male David (1998) *Immunology*. Mosby international Ltd.
4. Bainton, D.F., Ullyot, J.L., Farquhar, M.G. (1971) The development of neutrophilic polymorphonuclear leukocytes in human bone marrow. In *J Exp Med*, Volume 134 907-34.
5. Borregaard, N., Cowland, J.B. (1997) Granules of the human neutrophilic polymorphonuclear leukocyte. In *Blood*, Volume 89 3503-21.
6. Bainton, D.F., Farquhar, M.G. (1966) Origin of granules in polymorphonuclear leukocytes. Two types derived from opposite faces of the Golgi complex in developing granulocytes. In *J Cell Biol*, Volume 28 277-301.
7. Rice, W.G., Ganz, T., Kinkade, J.M., Jr., Selsted, M.E., Lehrer, R.I., Parmley, R.T. (1987) Defensin-rich dense granules of human neutrophils. In *Blood*, Volume 70 757-65.
8. Oren, A., Taylor, J.M. (1995) The subcellular localization of defensins and myeloperoxidase in human neutrophils: immunocytochemical evidence for azurophil granule heterogeneity. In *J Lab Clin Med*, Volume 125 340-7.
9. Kjeldsen, L., Bainton, D.F., Sengelov, H., Borregaard, N. (1993) Structural and functional heterogeneity among peroxidase-negative granules in human neutrophils: identification of a distinct gelatinase-containing granule subset by combined immunocytochemistry and subcellular fractionation. In *Blood*, Volume 82 3183-91.
10. Egesten, A., Breton-Gorius, J., Guichard, J., Gullberg, U., Olsson, I. (1994) The heterogeneity of azurophil granules in neutrophil promyelocytes: immunogold localization of myeloperoxidase, cathepsin G, elastase, proteinase 3, and bactericidal/permeability increasing protein. In *Blood*, Volume 83 2985-94.
11. Arnljots, K., Sorensen, O., Lollike, K., Borregaard, N. (1998) Timing, targeting and sorting of azurophil granule proteins in human myeloid cells. In *Leukemia*, Volume 12 1789-95.
12. Le Cabec, V., Calafat, J., Borregaard, N. (1997) Sorting of the specific granule protein, NGAL, during granulocytic maturation of HL-60 cells. In *Blood*, Volume 89 2113-21.
13. Gullberg, U., Andersson, E., Garwicz, D., Lindmark, A., Olsson, I. (1997) Biosynthesis, processing and sorting of neutrophil proteins: insight into neutrophil granule development. In *Eur J Haematol*, Volume 58 137-53.
14. Skalnik, D.G. (2002) Transcriptional mechanisms regulating myeloid-specific genes. In *Gene*, Volume 284 1-21.
15. Friedman, A.D. (2002) Transcriptional regulation of myelopoiesis. In *Int J Hematol*, Volume 75 466-72.

16. DeKoter, R.P., Walsh, J.C., Singh, H. (1998) PU.1 regulates both cytokine-dependent proliferation and differentiation of granulocyte/macrophage progenitors. In *Embo J*, Volume 17 4456-68.
17. McKercher, S.R., Torbett, B.E., Anderson, K.L., Henkel, G.W., Vestal, D.J., Baribault, H., Klemsz, M., Feeney, A.J., Wu, G.E., Paige, C.J., Maki, R.A. (1996) Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. In *Embo J*, Volume 15 5647-58.
18. Henkel, G.W., McKercher, S.R., Yamamoto, H., Anderson, K.L., Oshima, R.G., Maki, R.A. (1996) PU.1 but not ets-2 is essential for macrophage development from embryonic stem cells. In *Blood*, Volume 88 2917-26.
19. Zhang, D.E., Fujioka, K., Hetherington, C.J., Shapiro, L.H., Chen, H.M., Look, A.T., Tenen, D.G. (1994) Identification of a region which directs the monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1). In *Mol Cell Biol*, Volume 14 8085-95.
20. Tenen, D.G. (2003) Disruption of differentiation in human cancer: AML shows the way. In *Nat Rev Cancer*, Volume 3 89-101.
21. Reddy, V.A., Iwama, A., Iotzova, G., Schulz, M., Elsasser, A., Vangala, R.K., Tenen, D.G., Hiddemann, W., Behre, G. (2002) Granulocyte inducer C/EBPalpha inactivates the myeloid master regulator PU.1: possible role in lineage commitment decisions. In *Blood*, Volume 100 483-90.
22. Radomska, H.S., Huettner, C.S., Zhang, P., Cheng, T., Scadden, D.T., Tenen, D.G. (1998) CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. In *Mol Cell Biol*, Volume 18 4301-14.
23. Hohaus, S., Petrovick, M.S., Voso, M.T., Sun, Z., Zhang, D.E., Tenen, D.G. (1995) PU.1 (Spi-1) and C/EBP alpha regulate expression of the granulocyte-macrophage colony-stimulating factor receptor alpha gene. In *Mol Cell Biol*, Volume 15 5830-45.
24. Smith, L.T., Hohaus, S., Gonzalez, D.A., Dziennis, S.E., Tenen, D.G. (1996) PU.1 (Spi-1) and C/EBP alpha regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells. In *Blood*, Volume 88 1234-47.
25. Iwama, A., Zhang, P., Darlington, G.J., McKercher, S.R., Maki, R., Tenen, D.G. (1998) Use of RDA analysis of knockout mice to identify myeloid genes regulated in vivo by PU.1 and C/EBPalpha. In *Nucleic Acids Res*, Volume 26 3034-43.
26. Anderson, K.L., Smith, K.A., Pio, F., Torbett, B.E., Maki, R.A. (1998) Neutrophils deficient in PU.1 do not terminally differentiate or become functionally competent. In *Blood*, Volume 92 1576-85.
27. Anderson, K.L., Smith, K.A., Connors, K., McKercher, S.R., Maki, R.A., Torbett, B.E. (1998) Myeloid development is selectively disrupted in PU.1 null mice. In *Blood*, Volume 91 3702-10.
28. Henkel, G.W., McKercher, S.R., Leenen, P.J., Maki, R.A. (1999) Commitment to the monocytic lineage occurs in the absence of the transcription factor PU.1. In *Blood*, Volume 93 2849-58.

29. Zhang, D.E., Zhang, P., Wang, N.D., Hetherington, C.J., Darlington, G.J., Tenen, D.G. (1997) Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. In *Proc Natl Acad Sci U S A*, Volume 94 569-74.
30. Liu, F., Wu, H.Y., Wesselschmidt, R., Kornaga, T., Link, D.C. (1996) Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. In *Immunity*, Volume 5 491-501.
31. Rausch, O., Marshall, C.J. (1997) Tyrosine 763 of the murine granulocyte colony-stimulating factor receptor mediates Ras-dependent activation of the JNK/SAPK mitogen-activated protein kinase pathway. In *Mol Cell Biol*, Volume 17 1170-9.
32. Behre, G., Whitmarsh, A.J., Coghlan, M.P., Hoang, T., Carpenter, C.L., Zhang, D.E., Davis, R.J., Tenen, D.G. (1999) c-Jun is a JNK-independent coactivator of the PU.1 transcription factor. In *J Biol Chem*, Volume 274 4939-46.
33. Tenen, D.G., Hromas, R., Licht, J.D., Zhang, D.E. (1997) Transcription factors, normal myeloid development, and leukemia. In *Blood*, Volume 90 489-519.
34. Scott, E.W., Simon, M.C., Anastasi, J., Singh, H. (1994) Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. In *Science*, Volume 265 1573-7.
35. Anderson, K.L., Smith, K.A., Perkin, H., Hermanson, G., Anderson, C.G., Jolly, D.J., Maki, R.A., Torbett, B.E. (1999) PU.1 and the granulocyte- and macrophage colony-stimulating factor receptors play distinct roles in late-stage myeloid cell differentiation. In *Blood*, Volume 94 2310-8.
36. Giguere, V., Ong, E.S., Segui, P., Evans, R.M. (1987) Identification of a receptor for the morphogen retinoic acid. In *Nature*, Volume 330 624-9.
37. Petkovich, M., Brand, N.J., Krust, A., Chambon, P. (1987) A human retinoic acid receptor which belongs to the family of nuclear receptors. In *Nature*, Volume 330 444-50.
38. Lawson, N.D., Berliner, N. (1999) Neutrophil maturation and the role of retinoic acid. In *Exp Hematol*, Volume 27 1355-67.
39. Tsai, S., Collins, S.J. (1993) A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocyte stage. In *Proc Natl Acad Sci U S A*, Volume 90 7153-7.
40. Morosetti, R., Park, D.J., Chumakov, A.M., Grillier, I., Shiohara, M., Gombart, A.F., Nakamaki, T., Weinberg, K., Koeffler, H.P. (1997) A novel, myeloid transcription factor, C/EBP epsilon, is upregulated during granulocytic, but not monocytic, differentiation. In *Blood*, Volume 90 2591-600.
41. Yamanaka, R., Kim, G.D., Radomska, H.S., Lekstrom-Himes, J., Smith, L.T., Antonson, P., Tenen, D.G., Xanthopoulos, K.G. (1997) CCAAT/enhancer binding protein epsilon is preferentially up-regulated during granulocytic differentiation and its functional versatility is determined by alternative use of promoters and differential splicing. In *Proc Natl Acad Sci U S A*, Volume 94 6462-7.

42. Chih, D.Y., Chumakov, A.M., Park, D.J., Silla, A.G., Koeffler, H.P. (1997) Modulation of mRNA expression of a novel human myeloid-selective CCAAT/enhancer binding protein gene (C/EBP epsilon). In *Blood*, Volume 90 2987-94.
43. Park, D.J., Chumakov, A.M., Vuong, P.T., Chih, D.Y., Gombart, A.F., Miller, W.H., Jr., Koeffler, H.P. (1999) CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment. In *J Clin Invest*, Volume 103 1399-408.
44. Frank, R., Zhang, J., Uchida, H., Meyers, S., Hiebert, S.W., Nimer, S.D. (1995) The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. In *Oncogene*, Volume 11 2667-74.
45. Nuchprayoon, I., Meyers, S., Scott, L.M., Suzow, J., Hiebert, S., Friedman, A.D. (1994) PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2 beta/CBF beta proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells. In *Mol Cell Biol*, Volume 14 5558-68.
46. Miyoshi, H., Shimizu, K., Kozu, T., Maseki, N., Kaneko, Y., Ohki, M. (1991) t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. In *Proc Natl Acad Sci U S A*, Volume 88 10431-4.
47. Downing, J.R. (1999) The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance. In *Br J Haematol*, Volume 106 296-308.
48. Westendorf, J.J., Yamamoto, C.M., Lenny, N., Downing, J.R., Selsted, M.E., Hiebert, S.W. (1998) The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. In *Mol Cell Biol*, Volume 18 322-33.
49. Vangala, R.K., Heiss-Neumann, M.S., Rangatia, J.S., Singh, S.M., Schoch, C., Tenen, D.G., Hiddemann, W., Behre, G. (2003) The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. In *Blood*, Volume 101 270-7.
50. Mueller, B.U., Pabst, T., Osato, M., Asou, N., Johansen, L.M., Minden, M.D., Behre, G., Hiddemann, W., Ito, Y., Tenen, D.G. (2002) Heterozygous PU.1 mutations are associated with acute myeloid leukemia. In *Blood*, Volume 100 998-1007.
51. Pabst, T., Mueller, B.U., Zhang, P., Radomska, H.S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., Tenen, D.G. (2001) Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. In *Nat Genet*, Volume 27 263-70.
52. Goddard, A.D., Borrow, J., Freemont, P.S., Solomon, E. (1991) Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. In *Science*, Volume 254 1371-4.
53. Kakizuka, A., Miller, W.H., Jr., Umesono, K., Warrell, R.P., Jr., Frankel, S.R., Murty, V.V., Dmitrovsky, E., Evans, R.M. (1991) Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. In *Cell*, Volume 66 663-74.

54. de The, H., Lavau, C., Marchio, A., Chomienne, C., Degos, L., Dejean, A. (1991) The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. In *Cell*, Volume 66 675-84.
55. Lekstrom-Himes, J.A. (2001) The role of c/ebpvarepsilon in the terminal stages of granulocyte differentiation. In *Stem Cells*, Volume 19 125-33.
56. Truong, B.T., Lee, Y.J., Lodie, T.A., Park, D.J., Perrotti, D., Watanabe, N., Koefler, H.P., Nakajima, H., Tenen, D.G., Kogan, S.C. (2003) CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia. In *Blood*, Volume 101 1141-8. Epub 2002 Oct 3.
57. Huang, M.E., Ye, Y.C., Chen, S.R., Chai, J.R., Lu, J.X., Zhou, L., Gu, L.J., Wang, Z.Y. (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. In *Blood*, Volume 72 567-72.
58. Wong, C.W., Privalsky, M.L. (1998) Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARalpha, and BCL-6. In *J Biol Chem*, Volume 273 27695-702.
59. He, L.Z., Tolentino, T., Grayson, P., Zhong, S., Warrell, R.P., Jr., Rifkind, R.A., Marks, P.A., Richon, V.M., Pandolfi, P.P. (2001) Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. In *J Clin Invest*, Volume 108 1321-30.
60. Gombart, A.F., Koefler, H.P. (2002) Neutrophil specific granule deficiency and mutations in the gene encoding transcription factor C/EBP(epsilon). In *Curr Opin Hematol*, Volume 9 36-42.
61. Lekstrom-Himes, J.A., Dorman, S.E., Kopar, P., Holland, S.M., Gallin, J.I. (1999) Neutrophil-specific granule deficiency results from a novel mutation with loss of function of the transcription factor CCAAT/enhancer binding protein epsilon. In *J Exp Med*, Volume 189 1847-52.
62. Johnston, J.J., Boxer, L.A., Berliner, N. (1992) Correlation of messenger RNA levels with protein defects in specific granule deficiency. In *Blood*, Volume 80 2088-91.
63. Austin, G.E., Zhao, W.G., Zhang, W., Austin, E.D., Findley, H.W., Murtagh, J.J., Jr. (1995) Identification and characterization of the human myeloperoxidase promoter. In *Leukemia*, Volume 9 848-57.
64. Austin, G.E., Zhao, W.G., Regmi, A., Lu, J.P., Braun, J. (1998) Identification of an upstream enhancer containing an AML1 site in the human myeloperoxidase (MPO) gene. In *Leuk Res*, Volume 22 1037-48.
65. Johnson, K., Gemperlein, I., Hudson, S., Shane, S., Rovera, G. (1989) Complete nucleotide sequence of the human myeloperoxidase gene. In *Nucleic Acids Res*, Volume 17 7985-6.
66. Venturelli, D., Bittenbender, S., Rovera, G. (1989) Sequence of the murine myeloperoxidase (MPO) gene. In *Nucleic Acids Res*, Volume 17 7987-8.
67. Zhao, W.G., Regmi, A., Austin, E.D., Braun, J.E., Racine, M., Austin, G.E. (1996) Cis-elements in the promoter region of the human myeloperoxidase (MPO) gene. In *Leukemia*, Volume 10 1089-103.

68. Zhao, W.G., Lu, J.P., Regmi, A., Austin, G.E. (1997) Identification and functional analysis of multiple murine myeloperoxidase (MPO) promoters and comparison with the human MPO promoter region. In *Leukemia*, Volume 11 97-105.
69. Chumakov, A.M., Chumakova, E.A., Chih, D., Koeffler, H.P. (2000) Molecular analysis of the human myeloperoxidase promoter region. In *Int J Oncol*, Volume 16 401-11.
70. Ford, A.M., Bennett, C.A., Healy, L.E., Towatari, M., Greaves, M.F., Enver, T. (1996) Regulation of the myeloperoxidase enhancer binding proteins Pu1, C-EBP alpha, -beta, and -delta during granulocyte-lineage specification. In *Proc Natl Acad Sci U S A*, Volume 93 10838-43.
71. Wang, X., Scott, E., Sawyers, C.L., Friedman, A.D. (1999) C/EBPalpha bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts. In *Blood*, Volume 94 560-71.
72. Britos-Bray, M., Friedman, A.D. (1997) Core binding factor cannot synergistically activate the myeloperoxidase proximal enhancer in immature myeloid cells without c-Myb. In *Mol Cell Biol*, Volume 17 5127-35.
73. Zimmer, M., Medcalf, R.L., Fink, T.M., Mattmann, C., Lichter, P., Jenne, D.E. (1992) Three human elastase-like genes coordinately expressed in the myelomonocyte lineage are organized as a single genetic locus on 19pter. In *Proc Natl Acad Sci U S A*, Volume 89 8215-9.
74. Sturrock, A. (1996) Human proteinase-3 expression is regulated by PU.1 in conjunction with a cytidine-rich element. In *The Journal of Biological Chemistry*, Volume 271 32392-32402.
75. Lutz, P.G. (2000) Myeloblastin is a granulocyte colony-stimulating factor-responsive gene conferring factor-independent growth to hematopoietic cells. In *PNAS*, Volume 97 1601-1606.
76. Lutz, P.G., Houzel-Charavel, A., Moog-Lutz, C., Cayre, Y.E. (2001) Myeloblastin is an Myb target gene: mechanisms of regulation in myeloid leukemia cells growth-arrested by retinoic acid. In *Blood*, Volume 97 2449-56.
77. Nuchprayoon, I., Shang, J., Simkevich, C.P., Luo, M., Rosmarin, A.G., Friedman, A.D. (1999) An enhancer located between the neutrophil elastase and proteinase 3 promoters is activated by Sp1 and an Ets factor. In *J Biol Chem*, Volume 274 1085-91.
78. Sturrock, A.B. (1992) Structure, chromosomal assignment, and expression of the gene for proteinase-3. In *The Journal of Biological Chemistry*, Volume 267 21193-21199.
79. Hanson, R.D., Connolly, N.L., Burnett, D., Campbell, E.J., Senior, R.M., Ley, T.J. (1990) Developmental regulation of the human cathepsin G gene in myelomonocytic cells. In *J Biol Chem*, Volume 265 1524-30.
80. Oelgeschlager, M., Nuchprayoon, I., Luscher, B., Friedman, A.D. (1996) C/EBP, c-Myb, and PU.1 cooperate to regulate the neutrophil elastase promoter. In *Mol Cell Biol*, Volume 16 4717-25.
81. Sturrock, A., Franklin, K.F., Wu, S., Hoidal, J.R. (1998) Characterization and localization of the genes for mouse proteinase-3 (Prtn3) and neutrophil elastase (Ela2). In *Cytogenet Cell Genet*, Volume 83 104-8.

82. Tsutsumi-Ishii, Y., Hasebe, T., Nagaoka, I. (2000) Role of CCAAT/enhancer-binding protein site in transcription of human neutrophil peptide-1 and -3 defensin genes. In *J Immunol*, Volume 164 3264-73.
83. Lievens, P.M., Donady, J.J., Tufarelli, C., Neufeld, E.J. (1995) Repressor activity of CCAAT displacement protein in HL-60 myeloid leukemia cells. In *J Biol Chem*, Volume 270 12745-50.
84. Skalnik, D.G., Strauss, E.C., Orkin, S.H. (1991) CCAAT displacement protein as a repressor of the myelomonocytic-specific gp91-phox gene promoter. In *J Biol Chem*, Volume 266 16736-44.
85. Catt, D., Hawkins, S., Roman, A., Luo, W., Skalnik, D.G. (1999) Overexpression of CCAAT displacement protein represses the promiscuously active proximal gp91(phox) promoter. In *Blood*, Volume 94 3151-60.
86. Khanna-Gupta, A., Zibello, T., Kolla, S., Neufeld, E.J., Berliner, N. (1997) CCAAT displacement protein (CDP/cut) recognizes a silencer element within the lactoferrin gene promoter. In *Blood*, Volume 90 2784-95.
87. Khanna-Gupta, A., Zibello, T., Sun, H., Gaines, P., Berliner, N. (2003) Chromatin immunoprecipitation (ChIP) studies indicate a role for CCAAT enhancer binding proteins alpha and epsilon (C/EBP alpha and C/EBP epsilon) and CDP/cut in myeloid maturation-induced lactoferrin gene expression. In *Blood*, Volume 101 3460-8.
88. Teng, C.T. (1994) Lactoferrin gene promoter in human and mouse. Analogous and dissimilar characteristics. In *Adv Exp Med Biol*, Volume 357 183-96.
89. Teng, C.T. (2002) Lactoferrin gene expression and regulation: an overview. In *Biochem Cell Biol*, Volume 80 7-16.
90. Verbeek, W., Lekstrom-Himes, J., Park, D.J., Dang, P.M., Vuong, P.T., Kawano, S., Babior, B.M., Xanthopoulos, K., Koeffler, H.P. (1999) Myeloid transcription factor C/EBPepsilon is involved in the positive regulation of lactoferrin gene expression in neutrophils. In *Blood*, Volume 94 3141-50.
91. Khanna-Gupta, A., Zibello, T., Simkevich, C., Rosmarin, A.G., Berliner, N. (2000) Sp1 and C/EBP are necessary to activate the lactoferrin gene promoter during myeloid differentiation. In *Blood*, Volume 95 3734-41.
92. Khanna-Gupta, A., Zibello, T., Idone, V., Sun, H., Lekstrom-Himes, J., Berliner, N. (2005) Human neutrophil collagenase expression is C/EBP-dependent during myeloid development. In *Exp Hematol*, Volume 33 42-52.
93. Khanna-Gupta, A., Kolibaba, K., Zibello, T.A., Berliner, N. (1994) NB4 cells show bilineage potential and an aberrant pattern of neutrophil secondary granule protein gene expression. In *Blood*, Volume 84 294-302.
94. Khanna-Gupta, A., Zibello, T., Berliner, N. (1996) Coordinate regulation of neutrophil secondary granule protein gene expression. In *Curr Top Microbiol Immunol*, Volume 211 165-71.

95. Borregaard, N., Theilgaard-Monch, K., Sorensen, O.E., Cowland, J.B. (2001) Regulation of human neutrophil granule protein expression. In *Curr Opin Hematol*, Volume 8 23-7.
96. Bjerregaard, M.D., Jurlander, J., Klausen, P., Borregaard, N., Cowland, J.B. (2003) The in vivo profile of transcription factors during neutrophil differentiation in human bone marrow. In *Blood*, Volume 30 30.
97. Klemsz, M.J., McKercher, S.R., Celada, A., Van Beveren, C., Maki, R.A. (1990) The macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene. In *Cell*, Volume 61 113-24.
98. Chen, H.M., Zhang, P., Voso, M.T., Hohaus, S., Gonzalez, D.A., Glass, C.K., Zhang, D.E., Tenen, D.G. (1995) Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B. In *Blood*, Volume 85 2918-28.
99. Lord, K.A., Abdollahi, A., Hoffman-Liebermann, B., Liebermann, D.A. (1993) Proto-oncogenes of the fos/jun family of transcription factors are positive regulators of myeloid differentiation. In *Mol Cell Biol*, Volume 13 841-51.
100. Rangatia, J., Vangala, R.K., Treiber, N., Zhang, P., Radomska, H., Tenen, D.G., Hiddemann, W., Behre, G. (2002) Downregulation of c-Jun expression by transcription factor C/EBPalpha is critical for granulocytic lineage commitment. In *Mol Cell Biol*, Volume 22 8681-94.
101. Voso, M.T., Burn, T.C., Wulf, G., Lim, B., Leone, G., Tenen, D.G. (1994) Inhibition of hematopoiesis by competitive binding of transcription factor PU.1. In *Proc Natl Acad Sci U S A*, Volume 91 7932-6.
102. Visvader, J.E., Elefanty, A.G., Strasser, A., Adams, J.M. (1992) GATA-1 but not SCL induces megakaryocytic differentiation in an early myeloid line. In *Embo J*, Volume 11 4557-64.
103. Rekhtman, N., Radparvar, F., Evans, T., Skoultchi, A.I. (1999) Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells. In *Genes Dev*, Volume 13 1398-411.
104. Zhang, P., Zhang, X., Iwama, A., Yu, C., Smith, K.A., Mueller, B.U., Narravula, S., Torbett, B.E., Orkin, S.H., Tenen, D.G. (2000) PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding. In *Blood*, Volume 96 2641-8.
105. Gauthier, J.M., Bourachot, B., Doucas, V., Yaniv, M., Moreau-Gachelin, F. (1993) Functional interference between the Spi-1/PU.1 oncoprotein and steroid hormone or vitamin receptors. In *Embo J*, Volume 12 5089-96.
106. Meraro, D., Hashmueli, S., Koren, B., Azriel, A., Oumard, A., Kirchhoff, S., Hauser, H., Nagulapalli, S., Atchison, M.L., Levi, B.Z. (1999) Protein-protein and DNA-protein interactions affect the activity of lymphoid-specific IFN regulatory factors. In *J Immunol*, Volume 163 6468-78.
107. Marecki, S., Riendeau, C.J., Liang, M.D., Fenton, M.J. (2001) PU.1 and multiple IFN regulatory factor proteins synergize to mediate transcriptional activation of the human IL-1 beta gene. In *J Immunol*, Volume 166 6829-38.

108. Iida, H., Towatari, M., Iida, M., Tanimoto, M., Kodera, Y., Ford, A.M., Saito, H. (2000) Protein expression and constitutive phosphorylation of hematopoietic transcription factors PU.1 and C/EBP beta in acute myeloid leukemia blasts. In *Int J Hematol*, Volume 71 153-8.
109. Mao, C., Ray-Gallet, D., Tavitian, A., Moreau-Gachelin, F. (1996) Differential phosphorylations of Spi-B and Spi-1 transcription factors. In *Oncogene*, Volume 12 863-73.
110. Celada, A., Borrás, F.E., Soler, C., Lloberas, J., Klemsz, M., van Beveren, C., McKercher, S., Maki, R.A. (1996) The transcription factor PU.1 is involved in macrophage proliferation. In *J Exp Med*, Volume 184 61-9.
111. Lékstrom-Himes, J., Xanthopoulos, K.G. (1998) Biological role of the CCAAT/enhancer-binding protein family of transcription factors. In *J Biol Chem*, Volume 273 28545-8.
112. Poli, V. (1998) The role of C/EBP isoforms in the control of inflammatory and native immunity functions. In *J Biol Chem*, Volume 273 29279-82.
113. Ramji, D.P., Foka, P. (2002) CCAAT/enhancer-binding proteins: structure, function and regulation. In *Biochem J*, Volume 365 561-75.
114. Landschulz, W.H., Johnson, P.F., McKnight, S.L. (1988) The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. In *Science*, Volume 240 1759-64.
115. Williams, S.C., Cantwell, C.A., Johnson, P.F. (1991) A family of C/EBP-related proteins capable of forming covalently linked leucine zipper dimers in vitro. In *Genes Dev*, Volume 5 1553-67.
116. Landschulz, W.H., Johnson, P.F., McKnight, S.L. (1989) The DNA binding domain of the rat liver nuclear protein C/EBP is bipartite. In *Science*, Volume 243 1681-8.
117. Vinson, C.R., Sigler, P.B., McKnight, S.L. (1989) Scissors-grip model for DNA recognition by a family of leucine zipper proteins. In *Science*, Volume 246 911-6.
118. Hurst, H.C. (1995) Transcription factors 1: bZIP proteins. In *Protein Profile*, Volume 2 101-68.
119. Ron, D., Habener, J.F. (1992) CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. In *Genes Dev*, Volume 6 439-53.
120. Cooper, C., Henderson, A., Artandi, S., Avitahl, N., Calame, K. (1995) Ig/EBP (C/EBP gamma) is a transdominant negative inhibitor of C/EBP family transcriptional activators. In *Nucleic Acids Res*, Volume 23 4371-7.
121. Vallejo, M., Ron, D., Miller, C.P., Habener, J.F. (1993) C/ATF, a member of the activating transcription factor family of DNA-binding proteins, dimerizes with CAAT/enhancer-binding proteins and directs their binding to cAMP response elements. In *Proc Natl Acad Sci U S A*, Volume 90 4679-83.
122. Stein, B., Baldwin, A.S., Jr. (1993) Distinct mechanisms for regulation of the interleukin-8 gene involve synergism and cooperativity between C/EBP and NF-kappa B. In *Mol Cell Biol*, Volume 13 7191-8.

123. Diehl, J.A., Hannink, M. (1994) Identification of a C/EBP-Rel complex in avian lymphoid cells. In *Mol Cell Biol*, Volume 14 6635-46.
124. Lee, Y.H., Yano, M., Liu, S.Y., Matsunaga, E., Johnson, P.F., Gonzalez, F.J. (1994) A novel cis-acting element controlling the rat CYP2D5 gene and requiring cooperativity between C/EBP beta and an Sp1 factor. In *Mol Cell Biol*, Volume 14 1383-94.
125. Ossipow, V., Descombes, P., Schibler, U. (1993) CCAAT/enhancer-binding protein mRNA is translated into multiple proteins with different transcription activation potentials. In *Proc Natl Acad Sci U S A*, Volume 90 8219-23.
126. Descombes, P., Schibler, U. (1991) A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. In *Cell*, Volume 67 569-79.
127. Verbeek, W., Gombart, A.F., Chumakov, A.M., Muller, C., Friedman, A.D., Koeffler, H.P. (1999) C/EBPepsilon directly interacts with the DNA binding domain of c-myb and cooperatively activates transcription of myeloid promoters. In *Blood*, Volume 93 3327-37.
128. Scott, L.M., Civin, C.I., Rorth, P., Friedman, A.D. (1992) A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells. In *Blood*, Volume 80 1725-35.
129. Antonson, P., Stellan, B., Yamanaka, R., Xanthopoulos, K.G. (1996) A novel human CCAAT/enhancer binding protein gene, C/EBPepsilon, is expressed in cells of lymphoid and myeloid lineages and is localized on chromosome 14q11.2 close to the T-cell receptor alpha/delta locus. In *Genomics*, Volume 35 30-8.
130. Chumakov, A.M., Grillier, I., Chumakova, E., Chih, D., Slater, J., Koeffler, H.P. (1997) Cloning of the novel human myeloid-cell-specific C/EBP-epsilon transcription factor. In *Mol Cell Biol*, Volume 17 1375-86.
131. Antonson, P., Xanthopoulos, K.G. (1995) Molecular cloning, sequence, and expression patterns of the human gene encoding CCAAT/enhancer binding protein alpha (C/EBP alpha). In *Biochem Biophys Res Commun*, Volume 215 106-13.
132. Meyers, S., Downing, J.R., Hiebert, S.W. (1993) Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. In *Mol Cell Biol*, Volume 13 6336-45.
133. Wang, S., Wang, Q., Crute, B.E., Melnikova, I.N., Keller, S.R., Speck, N.A. (1993) Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. In *Mol Cell Biol*, Volume 13 3324-39.
134. Ogawa, E., Inuzuka, M., Maruyama, M., Satake, M., Naito-Fujimoto, M., Ito, Y., Shigesada, K. (1993) Molecular cloning and characterization of PEBP2 beta, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2 alpha. In *Virology*, Volume 194 314-31.
135. Mao, S., Frank, R.C., Zhang, J., Miyazaki, Y., Nimer, S.D. (1999) Functional and physical interactions between AML1 proteins and an ETS

- protein, MEF: implications for the pathogenesis of t(8;21)-positive leukemias. In *Mol Cell Biol*, Volume 19 3635-44.
136. Petrovick, M.S., Hiebert, S.W., Friedman, A.D., Hetherington, C.J., Tenen, D.G., Zhang, D.E. (1998) Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1. In *Mol Cell Biol*, Volume 18 3915-25.
 137. Tanaka, T., Kurokawa, M., Ueki, K., Tanaka, K., Imai, Y., Mitani, K., Okazaki, K., Sagata, N., Yazaki, Y., Shibata, Y., Kadowaki, T., Hirai, H. (1996) The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability. In *Mol Cell Biol*, Volume 16 3967-79.
 138. Zhu, X., Yeadon, J.E., Burden, S.J. (1994) AML1 is expressed in skeletal muscle and is regulated by innervation. In *Mol Cell Biol*, Volume 14 8051-7.
 139. Cheng, T., Shen, H., Giokas, D., Gere, J., Tenen, D.G., Scadden, D.T. (1996) Temporal mapping of gene expression levels during the differentiation of individual primary hematopoietic cells. In *Proc Natl Acad Sci U S A*, Volume 93 13158-63.
 140. Emili, A., Greenblatt, J., Ingles, C.J. (1994) Species-specific interaction of the glutamine-rich activation domains of Sp1 with the TATA box-binding protein. In *Mol Cell Biol*, Volume 14 1582-93.
 141. Kadonaga, J.T., Carner, K.R., Masiarz, F.R., Tjian, R. (1987) Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. In *Cell*, Volume 51 1079-90.
 142. Bouwman, P., Philipsen, S. (2002) Regulation of the activity of Sp1-related transcription factors. In *Mol Cell Endocrinol*, Volume 195 27-38.
 143. Lania, L., Majello, B., De Luca, P. (1997) Transcriptional regulation by the Sp family proteins. In *Int J Biochem Cell Biol*, Volume 29 1313-23.
 144. Resendes, K.K., Rosmarin, A.G. (2004) Sp1 control of gene expression in myeloid cells. In *Crit Rev Eukaryot Gene Expr*, Volume 14 171-81.
 145. Majello, B., De Luca, P., Lania, L. (1997) Sp3 is a bifunctional transcription regulator with modular independent activation and repression domains. In *J Biol Chem*, Volume 272 4021-6.
 146. Saffer, J.D., Jackson, S.P., Annarella, M.B. (1991) Developmental expression of Sp1 in the mouse. In *Mol Cell Biol*, Volume 11 2189-99.
 147. Muller, S., Maas, A., Islam, T.C., Sideras, P., Suske, G., Philipsen, S., Xanthopoulos, K.G., Hendriks, R.W., Smith, C.I. (1999) Synergistic activation of the human Btk promoter by transcription factors Sp1/3 and PU.1. In *Biochem Biophys Res Commun*, Volume 259 364-9.
 148. Blobel, G.A. (2000) CREB-binding protein and p300: molecular integrators of hematopoietic transcription. In *Blood*, Volume 95 745-55.
 149. Suzuki, T., Kimura, A., Nagai, R., Horikoshi, M. (2000) Regulation of interaction of the acetyltransferase region of p300 and the DNA-binding domain of Sp1 on and through DNA binding. In *Genes Cells*, Volume 5 29-41.
 150. Black, A.R., Black, J.D., Azizkhan-Clifford, J. (2001) Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. In *J Cell Physiol*, Volume 188 143-60.

151. Rohlff, C., Ahmad, S., Borellini, F., Lei, J., Glazer, R.I. (1997) Modulation of transcription factor Sp1 by cAMP-dependent protein kinase. In *J Biol Chem*, Volume 272 21137-41.
152. Armstrong, S.A., Barry, D.A., Leggett, R.W., Mueller, C.R. (1997) Casein kinase II-mediated phosphorylation of the C terminus of Sp1 decreases its DNA binding activity. In *J Biol Chem*, Volume 272 13489-95.
153. Braun, H., Koop, R., Ertmer, A., Nacht, S., Suske, G. (2001) Transcription factor Sp3 is regulated by acetylation. In *Nucleic Acids Res*, Volume 29 4994-5000.
154. Sapetschnig, A., Rischitor, G., Braun, H., Doll, A., Schergaut, M., Melchior, F., Suske, G. (2002) Transcription factor Sp3 is silenced through SUMO modification by PIAS1. In *Embo J*, Volume 21 5206-15.
155. Verger, A., Perdomo, J., Crossley, M. (2003) Modification with SUMO. A role in transcriptional regulation. In *EMBO Rep*, Volume 4 137-42.
156. Barberis, A., Superti-Furga, G., Busslinger, M. (1987) Mutually exclusive interaction of the CCAAT-binding factor and of a displacement protein with overlapping sequences of a histone gene promoter. In *Cell*, Volume 50 347-59.
157. Neufeld, E.J., Skalnik, D.G., Lievens, P.M., Orkin, S.H. (1992) Human CCAAT displacement protein is homologous to the Drosophila homeoprotein, cut. In *Nat Genet*, Volume 1 50-5.
158. Moon, N.S., Premdas, P., Truscott, M., Leduy, L., Berube, G., Nepveu, A. (2001) S phase-specific proteolytic cleavage is required to activate stable DNA binding by the CDP/Cut homeodomain protein. In *Mol Cell Biol*, Volume 21 6332-45.
159. Orphanides, G., Lagrange, T., Reinberg, D. (1996) The general transcription factors of RNA polymerase II. In *Genes Dev*, Volume 10 2657-83.
160. Hampsey, M. (1998) Molecular genetics of the RNA polymerase II general transcriptional machinery. In *Microbiol Mol Biol Rev*, Volume 62 465-503.
161. Myer, V.E., Young, R.A. (1998) RNA polymerase II holoenzymes and subcomplexes. In *J Biol Chem*, Volume 273 27757-60.
162. Pugh, B.F. (2000) Control of gene expression through regulation of the TATA-binding protein. In *Gene*, Volume 255 1-14.
163. Emami, K.H., Jain, A., Smale, S.T. (1997) Mechanism of synergy between TATA and initiator: synergistic binding of TFIID following a putative TFIIA-induced isomerization. In *Genes Dev*, Volume 11 3007-19.
164. Martinez, E., Ge, H., Tao, Y., Yuan, C.X., Palhan, V., Roeder, R.G. (1998) Novel cofactors and TFIIA mediate functional core promoter selectivity by the human TAFII150-containing TFIID complex. In *Mol Cell Biol*, Volume 18 6571-83.
165. Smale, S.T. (1997) Transcription initiation from TATA-less promoters within eukaryotic protein-coding genes. In *Biochim Biophys Acta*, Volume 1351 73-88.
166. Johnson, P.F., McKnight, S.L. (1989) Eukaryotic transcriptional regulatory proteins. In *Annu Rev Biochem*, Volume 58 799-839.

167. Triezenberg, S.J. (1995) Structure and function of transcriptional activation domains. In *Curr Opin Genet Dev*, Volume 5 190-6.
168. Carey, M. (1998) The enhanceosome and transcriptional synergy. In *Cell*, Volume 92 5-8.
169. Merika, M., Thanos, D. (2001) Enhanceosomes. In *Curr Opin Genet Dev*, Volume 11 205-8.
170. Rippe, K., von Hippel, P.H., Langowski, J. (1995) Action at a distance: DNA-looping and initiation of transcription. In *Trends Biochem Sci*, Volume 20 500-6.
171. Torchia, J., Glass, C., Rosenfeld, M.G. (1998) Co-activators and co-repressors in the integration of transcriptional responses. In *Curr Opin Cell Biol*, Volume 10 373-83.
172. Carey M, S.S. (2000) Transcriptional regulation in eukaryotes. Cold Spring Harbor Laboratory Press, New York.
173. Workman, J.L., Kingston, R.E. (1998) Alteration of nucleosome structure as a mechanism of transcriptional regulation. In *Annu Rev Biochem*, Volume 67 545-79.
174. Urnov, F.D., Wolffe, A.P., Guschin, D. (2001) Molecular mechanisms of corepressor function. In *Curr Top Microbiol Immunol*, Volume 254 1-33.
175. Rietveld, L.E., Caldenhoven, E., Stunnenberg, H.G. (2001) Avian erythroleukemia: a model for corepressor function in cancer. In *Oncogene*, Volume 20 3100-9.
176. Grunstein, M. (1997) Histone acetylation in chromatin structure and transcription. In *Nature*, Volume 389 349-52.
177. Licht, J.D. (2001) Targeting aberrant transcriptional repression in leukemia: a therapeutic reality? In *J Clin Invest*, Volume 108 1277-8.
178. Alberts B, J.A., Lewis J, Raff M, Roberts K, Walter P (2002) Molecular Biology of the cell. Garland Science.
179. Ogbourne, S., Antalis, T.M. (1998) Transcriptional control and the role of silencers in transcriptional regulation in eukaryotes. In *Biochem J*, Volume 331 (Pt 1) 1-14.
180. Hoffmann, J.A., Kafatos, F.C., Janeway, C.A., Ezekowitz, R.A. (1999) Phylogenetic perspectives in innate immunity. In *Science*, Volume 284 1313-8.
181. Janeway, C.A., Jr., Medzhitov, R. (2002) Innate immune recognition. In *Annu Rev Immunol*, Volume 20 197-216.
182. Maianski, N.A., Maianski, A.N., Kuijpers, T.W., Roos, D. (2004) Apoptosis of neutrophils. In *Acta Haematol*, Volume 111 56-66.
183. Burg, N.D., Pillinger, M.H. (2001) The neutrophil: function and regulation in innate and humoral immunity. In *Clin Immunol*, Volume 99 7-17.
184. Djaldetti, M., Salman, H., Bergman, M., Djaldetti, R., Bessler, H. (2002) Phagocytosis--the mighty weapon of the silent warriors. In *Microsc Res Tech*, Volume 57 421-31.
185. Yadav, R., Larbi, K.Y., Young, R.E., Nourshargh, S. (2003) Migration of leukocytes through the vessel wall and beyond. In *Thromb Haemost*, Volume 90 598-606.

186. Nourshargh, S., Marelli-Berg, F.M. (2005) Transmigration through venular walls: a key regulator of leukocyte phenotype and function. In *Trends Immunol*, Volume 26 157-65.
187. Harris, E.S., McIntyre, T.M., Prescott, S.M., Zimmerman, G.A. (2000) The leukocyte integrins. In *J Biol Chem*, Volume 275 23409-12.
188. Babior, B.M. (1999) NADPH oxidase: an update. In *Blood*, Volume 93 1464-76.
189. Hampton, M.B., Kettle, A.J., Winterbourn, C.C. (1998) Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. In *Blood*, Volume 92 3007-17.
190. Murray, H.W., Cartelli, D.M. (1983) Killing of intracellular *Leishmania donovani* by human mononuclear phagocytes. Evidence for oxygen-dependent and -independent leishmanicidal activity. In *J Clin Invest*, Volume 72 32-44.
191. Gordon, S. (1999) Inflammation: Basic Principles and clinical correlates.
192. Levy, O. (2000) Antimicrobial proteins and peptides of blood: templates for novel antimicrobial agents. In *Blood*, Volume 96 2664-72.
193. Chapple, D.S., Mason, D.J., Joannou, C.L., Odell, E.W., Gant, V., Evans, R.W. (1998) Structure-function relationship of antibacterial synthetic peptides homologous to a helical surface region on human lactoferrin against *Escherichia coli* serotype O111. In *Infect Immun*, Volume 66 2434-40.
194. Kuwata, H., Yip, T.T., Yip, C.L., Tomita, M., Hutchens, T.W. (1998) Bactericidal domain of lactoferrin: detection, quantitation, and characterization of lactoferrin in serum by SELDI affinity mass spectrometry. In *Biochem Biophys Res Commun*, Volume 245 764-73.
195. Ellass-Rochard, E., Legrand, D., Salmon, V., Roseanu, A., Trif, M., Tobias, P.S., Mazurier, J., Spik, G. (1998) Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. In *Infect Immun*, Volume 66 486-91.
196. Gabay, J.E., Almeida, R.P. (1993) Antibiotic peptides and serine protease homologs in human polymorphonuclear leukocytes: defensins and azurocidin. In *Curr Opin Immunol*, Volume 5 97-102.
197. Campanelli, D., Detmers, P.A., Nathan, C.F., Gabay, J.E. (1990) Azurocidin and a homologous serine protease from neutrophils. Differential antimicrobial and proteolytic properties. In *J Clin Invest*, Volume 85 904-15.
198. Gallo, R.L., Murakami, M., Ohtake, T., Zaiou, M. (2002) Biology and clinical relevance of naturally occurring antimicrobial peptides. In *J Allergy Clin Immunol*, Volume 110 823-31.
199. Oppenheim, J.J., Biragyn, A., Kwak, L.W., Yang, D. (2003) Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. In *Ann Rheum Dis*, Volume 62 Suppl 2 ii17-21.
200. Ganz, T. (2003) Defensins: antimicrobial peptides of innate immunity. In *Nat Rev Immunol*, Volume 3 710-20.
201. Selsted, M.E., Ouellette, A.J. (1995) Defensins in granules of phagocytic and non-phagocytic cells. In *Trends Cell Biol*, Volume 5 114-9.
202. Agerberth, B., Charo, J., Werr, J., Olsson, B., Idali, F., Lindbom, L., Kiessling, R., Jornvall, H., Wigzell, H., Gudmundsson, G.H. (2000) The

- human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. In *Blood*, Volume 96 3086-93.
203. Fellermann, K., Stange, E.F. (2001) Defensins -- innate immunity at the epithelial frontier. In *Eur J Gastroenterol Hepatol*, Volume 13 771-6.
 204. Ganz, T. (2002) Antimicrobial polypeptides in host defense of the respiratory tract. In *J Clin Invest*, Volume 109 693-7.
 205. Duits, L.A., Ravensbergen, B., Rademaker, M., Hiemstra, P.S., Nibbering, P.H. (2002) Expression of beta-defensin 1 and 2 mRNA by human monocytes, macrophages and dendritic cells. In *Immunology*, Volume 106 517-25.
 206. Eisenhauer, P.B., Lehrer, R.I. (1992) Mouse neutrophils lack defensins. In *Infect Immun*, Volume 60 3446-7.
 207. Eisenhauer, P.B., Harwig, S.S., Szklarek, D., Ganz, T., Selsted, M.E., Lehrer, R.I. (1989) Purification and antimicrobial properties of three defensins from rat neutrophils. In *Infect Immun*, Volume 57 2021-7.
 208. Ouellette, A.J., Greco, R.M., James, M., Frederick, D., Naftilan, J., Fallon, J.T. (1989) Developmental regulation of cryptdin, a corticostatin/defensin precursor mRNA in mouse small intestinal crypt epithelium. In *J Cell Biol*, Volume 108 1687-95.
 209. Ouellette, A.J., Selsted, M.E. (1996) Paneth cell defensins: endogenous peptide components of intestinal host defense. In *Faseb J*, Volume 10 1280-9.
 210. Com, E., Bourgeon, F., Evrard, B., Ganz, T., Colletu, D., Jegou, B., Pineau, C. (2003) Expression of antimicrobial defensins in the male reproductive tract of rats, mice, and humans. In *Biol Reprod*, Volume 68 95-104.
 211. Burd, R.S., Furrer, J.L., Sullivan, J., Smith, A.L. (2002) Murine beta-defensin-3 is an inducible peptide with limited tissue expression and broad-spectrum antimicrobial activity. In *Shock*, Volume 18 461-4.
 212. Elsbach, P., Weiss, J. (1998) Role of the bactericidal/permeability-increasing protein in host defence. In *Curr Opin Immunol*, Volume 10 45-9.
 213. Weiss, J., Elsbach, P., Olsson, I., Odeberg, H. (1978) Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. In *J Biol Chem*, Volume 253 2664-72.
 214. Beamer, L.J., Carroll, S.F., Eisenberg, D. (1997) Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. In *Science*, Volume 276 1861-4.
 215. Gray, P.W., Corcoran, A.E., Eddy, R.L., Jr., Byers, M.G., Shows, T.B. (1993) The genes for the lipopolysaccharide binding protein (LBP) and the bactericidal permeability increasing protein (BPI) are encoded in the same region of human chromosome 20. In *Genomics*, Volume 15 188-90.
 216. Hubacek, J.A., Buchler, C., Aslanidis, C., Schmitz, G. (1997) The genomic organization of the genes for human lipopolysaccharide binding protein (LBP) and bactericidal permeability increasing protein (BPI) is highly conserved. In *Biochem Biophys Res Commun*, Volume 236 427-30.

217. Gray, P.W., Flaggs, G., Leong, S.R., Gumina, R.J., Weiss, J., Ooi, C.E., Elsbach, P. (1989) Cloning of the cDNA of a human neutrophil bactericidal protein. Structural and functional correlations. In *J Biol Chem*, Volume 264 9505-9.
218. Calafat, J., Janssen, H., Tool, A., Dentener, M.A., Knol, E.F., Rosenberg, H.F., Egesten, A. (1998) The bactericidal/permeability-increasing protein (BPI) is present in specific granules of human eosinophils. In *Blood*, Volume 91 4770-5.
219. Dentener, M.A., Francot, G.J., Buurman, W.A. (1996) Bactericidal/permeability-increasing protein, a lipopolysaccharide-specific protein on the surface of human peripheral blood monocytes. In *J Infect Dis*, Volume 173 252-5.
220. Canny, G., Levy, O., Furuta, G.T., Narravula-Alipati, S., Sisson, R.B., Serhan, C.N., Colgan, S.P. (2002) Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia. In *Proc Natl Acad Sci U S A*, Volume 99 3902-7.
221. Reichel, P.H., Seemann, C., Csernok, E., Schroder, J.M., Muller, A., Gross, W.L., Schultz, H. (2003) Bactericidal/Permeability-increasing protein is expressed by human dermal fibroblasts and upregulated by interleukin 4. In *Clin Diagn Lab Immunol*, Volume 10 473-5.
222. Mannion, B.A., Weiss, J., Elsbach, P. (1990) Separation of sublethal and lethal effects of polymorphonuclear leukocytes on *Escherichia coli*. In *J Clin Invest*, Volume 86 631-41.
223. Marra, M.N., Wilde, C.G., Griffith, J.E., Snable, J.L., Scott, R.W. (1990) Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. In *J Immunol*, Volume 144 662-6.
224. Iovine, N.M., Elsbach, P., Weiss, J. (1997) An opsonic function of the neutrophil bactericidal/permeability-increasing protein depends on both its N- and C-terminal domains. In *Proc Natl Acad Sci U S A*, Volume 94 10973-8.
225. Mannion, B.A., Kalatzis, E.S., Weiss, J., Elsbach, P. (1989) Preferential binding of the neutrophil cytoplasmic granule-derived bactericidal/permeability increasing protein to target bacteria. Implications and use as a means of purification. In *J Immunol*, Volume 142 2807-12.
226. Elsbach, P., Weiss, J., Levy, O. (1994) Integration of antimicrobial host defenses: role of the bactericidal/permeability-increasing protein. In *Trends Microbiol*, Volume 2 324-8.
227. Levy, O., Martin, S., Eichenwald, E., Ganz, T., Valore, E., Carroll, S.F., Lee, K., Goldmann, D., Thorne, G.M. (1999) Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability-increasing protein. In *Pediatrics*, Volume 104 1327-33.
228. Schultz, H., Weiss, J., Carroll, S.F., Gross, W.L. (2001) The endotoxin-binding bactericidal/permeability-increasing protein (BPI): a target antigen of autoantibodies. In *J Leukoc Biol*, Volume 69 505-12.
229. Levin, M., Quint, P.A., Goldstein, B., Barton, P., Bradley, J.S., Shemie, S.D., Yeh, T., Kim, S.S., Cafaro, D.P., Scannon, P.J., Giroir, B.P. (2000) Recombinant bactericidal/permeability-increasing protein (rBPI21) as

- adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. In *Lancet*, Volume 356 961-7.
230. Kirsch, E.A., Barton, R.P., Kitchen, L., Giroir, B.P. (1996) Pathophysiology, treatment and outcome of meningococemia: a review and recent experience. In *Pediatr Infect Dis J*, Volume 15 967-78; quiz 979.
 231. van Deuren, M., Brandtzaeg, P., van der Meer, J.W. (2000) Update on meningococcal disease with emphasis on pathogenesis and clinical management. In *Clin Microbiol Rev*, Volume 13 144-66, table of contents.
 232. Schumann, R.R., Leong, S.R., Flaggs, G.W., Gray, P.W., Wright, S.D., Mathison, J.C., Tobias, P.S., Ulevitch, R.J. (1990) Structure and function of lipopolysaccharide binding protein. In *Science*, Volume 249 1429-31.
 233. Wright, S.D., Ramos, R.A., Tobias, P.S., Ulevitch, R.J., Mathison, J.C. (1990) CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. In *Science*, Volume 249 1431-3.
 234. Fenton, M.J., Golenbock, D.T. (1998) LPS-binding proteins and receptors. In *J Leukoc Biol*, Volume 64 25-32.
 235. Ulevitch, R.J., Tobias, P.S. (1999) Recognition of gram-negative bacteria and endotoxin by the innate immune system. In *Curr Opin Immunol*, Volume 11 19-22.
 236. Weiss, J. (2003) Bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP): structure, function and regulation in host defence against Gram-negative bacteria. In *Biochem Soc Trans*, Volume 31 785-90.
 237. Tobias, P.S., Soldau, K., Iovine, N.M., Elsbach, P., Weiss, J. (1997) Lipopolysaccharide (LPS)-binding proteins BPI and LBP form different types of complexes with LPS. In *J Biol Chem*, Volume 272 18682-5.
 238. Beamer, L.J., Carroll, S.F., Eisenberg, D. (1998) The BPI/LBP family of proteins: a structural analysis of conserved regions. In *Protein Sci*, Volume 7 906-14.
 239. Colgan, S.P. (2002) Lipid mediators in epithelial cell-cell interactions. In *Cell Mol Life Sci*, Volume 59 754-60.
 240. Ganz, T. (2002) Epithelia: not just physical barriers. In *Proc Natl Acad Sci U S A*, Volume 99 3357-8.
 241. Bingle, C.D., Craven, C.J. (2004) Meet the relatives: a family of BPI- and LBP-related proteins. In *Trends Immunol*, Volume 25 53-5.
 242. Tall, A. (1995) Plasma lipid transfer proteins. In *Annu Rev Biochem*, Volume 64 235-57.
 243. Bingle, C.D., Bingle, L. (2000) Characterisation of the human plunc gene, a gene product with an upper airways and nasopharyngeal restricted expression pattern. In *Biochim Biophys Acta*, Volume 1493 363-7.
 244. Bingle, C.D., Craven, C.J. (2002) PLUNC: a novel family of candidate host defence proteins expressed in the upper airways and nasopharynx. In *Hum Mol Genet*, Volume 11 937-43.
 245. LeClair, E.E., Nguyen, L., Bingle, L., MacGowan, A., Singleton, V., Ward, S.J., Bingle, C.D. (2001) Genomic organization of the mouse

- plunc gene and expression in the developing airways and thymus. In *Biochem Biophys Res Commun*, Volume 284 792-7.
246. Leclair, E.E. (2003) Four BPI (bactericidal/permeability-increasing protein)-like genes expressed in the mouse nasal, oral, airway and digestive epithelia. In *Biochem Soc Trans*, Volume 31 801-5.
 247. Bingle, C.D., Gorr, S.U. (2004) Host defense in oral and airway epithelia: chromosome 20 contributes a new protein family. In *Int J Biochem Cell Biol*, Volume 36 2144-52.
 248. Andraut, J.B., Gaillard, I., Giorgi, D., Rouquier, S. (2003) Expansion of the BPI family by duplication on human chromosome 20: characterization of the RY gene cluster in 20q11.21 encoding olfactory transporters/antimicrobial-like peptides. In *Genomics*, Volume 82 172-84.
 249. Labbaye, C., Musette, P., Cayre, Y.E. (1991) Wegener autoantigen and myeloblastin are encoded by a single mRNA. In *Proc Natl Acad Sci U S A*, Volume 88 9253-6.
 250. van der Geld, Y.M., Limburg, P.C., Kallenberg, C.G. (2001) Proteinase 3, Wegener's autoantigen: from gene to antigen. In *J Leukoc Biol*, Volume 69 177-90.
 251. Witko-Sarsat, V., Cramer, E.M., Hieblot, C., Guichard, J., Nusbaum, P., Lopez, S., Lesavre, P., Halbwachs-Mecarelli, L. (1999) Presence of proteinase 3 in secretory vesicles: evidence of a novel, highly mobilizable intracellular pool distinct from azurophil granules. In *Blood*, Volume 94 2487-96.
 252. Halbwachs-Mecarelli, L. (1995) Bimodal distribution of proteinase 3 (PR3) surface expression reflects a constitutive heterogeneity in the polymorphonuclear neutrophil pool. In *FEBS letters*, Volume 374 29-33.
 253. Gabay, J.E., Scott, R.W., Campanelli, D., Griffith, J., Wilde, C., Marra, M.N., Seeger, M., Nathan, C.F. (1989) Antibiotic proteins of human polymorphonuclear leukocytes. In *Proc Natl Acad Sci U S A*, Volume 86 5610-4.
 254. Rao, N.V., Wehner, N.G., Marshall, B.C., Gray, W.R., Gray, B.H., Hoidal, J.R. (1991) Characterization of proteinase-3 (PR-3), a neutrophil serine proteinase. Structural and functional properties. In *J Biol Chem*, Volume 266 9540-8.
 255. Robache-Gallea, S., Morand, V., Bruneau, J.M., Schoot, B., Tagat, E., Realo, E., Chouaib, S., Roman-Roman, S. (1995) In vitro processing of human tumor necrosis factor-alpha. In *J Biol Chem*, Volume 270 23688-92.
 256. Padrines, M., Wolf, M., Walz, A., Baggiolini, M. (1994) Interleukin-8 processing by neutrophil elastase, cathepsin G and proteinase-3. In *FEBS Lett*, Volume 352 231-5.
 257. Berger, S.P., Seelen, M.A., Hiemstra, P.S., Gerritsma, J.S., Heemskerk, E., van der Woude, F.J., Daha, M.R. (1996) Proteinase 3, the major autoantigen of Wegener's granulomatosis, enhances IL-8 production by endothelial cells in vitro. In *J Am Soc Nephrol*, Volume 7 694-701.
 258. Goldschmeding, R., van der Schoot, C.E., ten Bokkel Huinink, D., Hack, C.E., van den Ende, M.E., Kallenberg, C.G., von dem Borne, A.E. (1989) Wegener's granulomatosis autoantibodies identify a novel

- diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. In *J Clin Invest*, Volume 84 1577-87.
259. Niles, J.L., McCluskey, R.T., Ahmad, M.F., Arnaout, M.A. (1989) Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase. In *Blood*, Volume 74 1888-93.
 260. Jennette, J.C., Hoidal, J.R., Falk, R.J. (1990) Specificity of anti-neutrophil cytoplasmic autoantibodies for proteinase 3. In *Blood*, Volume 75 2263-4.
 261. Fauci, A.S. (1983) Vasculitis. In *J Allergy Clin Immunol*, Volume 72 211-23.
 262. Segelmark, M., Westman, K., Wieslander, J. (2000) How and why should we detect ANCA? In *Clin Exp Rheumatol*, Volume 18 629-35.
 263. Boomsma, M.M., Stegeman, C.A., van der Leij, M.J., Oost, W., Hermans, J., Kallenberg, C.G., Limburg, P.C., Tervaert, J.W. (2000) Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. In *Arthritis Rheum*, Volume 43 2025-33.
 264. Lesavre, P. (1991) Antineutrophil cytoplasmic autoantibodies antigen specificity. In *Am J Kidney Dis*, Volume 18 159-63.
 265. Kallenberg, C.G., Rarok, A., Stegeman, C.A., Limburg, P.C. (2002) New insights into the pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis. In *Autoimmun Rev*, Volume 1 61-6.
 266. Schultz, H., Schinke, S., Mosler, K., Herlyn, K., Schuster, A., Gross, W.L. (2004) BPI-ANCA of pediatric cystic fibrosis patients can impair BPI-mediated killing of *E. coli* DH5alpha in vitro. In *Pediatr Pulmonol*, Volume 37 158-64.
 267. Schultz, H., Heintz, H., van Zandbergen, G., Ullrich, S., Reinhold-Keller, E., Gross, W.L. (2003) ANCA against the bactericidal/permeability increasing protein (BPI-ANCA) can compromise the antibiotic function of BPI in a Wegener's granulomatosis patient. In *Clin Exp Rheumatol*, Volume 21 763-6.
 268. Schreiber, A., Busjahn, A., Luft, F.C., Kettritz, R. (2003) Membrane expression of proteinase 3 is genetically determined. In *J Am Soc Nephrol*, Volume 14 68-75.
 269. Rarok, A.A. (2002) Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-Associated vasculitis. In *J. Am. Soc. Nephrol.*, Volume 13 2232-2238.
 270. Witko-Sarsat, V. (1999) A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis. In *J. Am. Soc. Nephrol.*, Volume 10 1224-1233.
 271. Yang, J.J., Tuttle, R.H., Hogan, S.L., Taylor, J.G., Phillips, B.D., Falk, R.J., Jennette, J.C. (2000) Target antigens for anti-neutrophil cytoplasmic autoantibodies (ANCA) are on the surface of primed and apoptotic but not unstimulated neutrophils. In *Clin Exp Immunol*, Volume 121 165-72.
 272. Csernok, E., Ernst, M., Schmitt, W., Bainton, D.F., Gross, W.L. (1994) Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. In *Clin Exp Immunol*, Volume 95 244-50.

273. Charles, L.A., Caldas, M.L., Falk, R.J., Terrell, R.S., Jennette, J.C. (1991) Antibodies against granule proteins activate neutrophils in vitro. In *J Leukoc Biol*, Volume 50 539-46.
274. Pall, A.A., Savage, C.O. (1994) Mechanisms of endothelial cell injury in vasculitis. In *Springer Semin Immunopathol*, Volume 16 23-37.
275. Savage, C.O., Pottinger, B.E., Gaskin, G., Pusey, C.D., Pearson, J.D. (1992) Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. In *Am J Pathol*, Volume 141 335-42.
276. van de Winkel, J.G., Capel, P.J. (1993) Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. In *Immunol Today*, Volume 14 215-21.
277. Dijstelbloem, H.M., van de Winkel, J.G., Kallenberg, C.G. (2001) Inflammation in autoimmunity: receptors for IgG revisited. In *Trends Immunol*, Volume 22 510-6.
278. Maxwell, K.F., Powell, M.S., Hulett, M.D., Barton, P.A., McKenzie, I.F., Garrett, T.P., Hogarth, P.M. (1999) Crystal structure of the human leukocyte Fc receptor, Fc gammaRIIa. In *Nat Struct Biol*, Volume 6 437-42.
279. Ben-Smith, A., Dove, S.K., Martin, A., Wakelam, M.J., Savage, C.O. (2001) Antineutrophil cytoplasm autoantibodies from patients with systemic vasculitis activate neutrophils through distinct signaling cascades: comparison with conventional Fc gamma receptor ligation. In *Blood*, Volume 98 1448-55.
280. Kettritz, R., Schreiber, A., Luft, F.C., Haller, H. (2001) Role of mitogen-activated protein kinases in activation of human neutrophils by antineutrophil cytoplasmic antibodies. In *J Am Soc Nephrol*, Volume 12 37-46.
281. Kettritz, R., Choi, M., Butt, W., Rane, M., Rolle, S., Luft, F.C., Klein, J.B. (2002) Phosphatidylinositol 3-kinase controls antineutrophil cytoplasmic antibodies-induced respiratory burst in human neutrophils. In *J Am Soc Nephrol*, Volume 13 1740-9.
282. Radford, D.J., Lord, J.M., Savage, C.O. (1999) The activation of the neutrophil respiratory burst by anti-neutrophil cytoplasm autoantibody (ANCA) from patients with systemic vasculitis requires tyrosine kinases and protein kinase C activation. In *Clin Exp Immunol*, Volume 118 171-9.
283. David, A., Kacher, Y., Specks, U., Aviram, I. (2003) Interaction of proteinase 3 with CD11b/CD18 (beta2 integrin) on the cell membrane of human neutrophils. In *J Leukoc Biol*, Volume 74 551-7.
284. Gilligan, H.M., Bredy, B., Brady, H.R., Hebert, M.J., Slayter, H.S., Xu, Y., Rauch, J., Shia, M.A., Koh, J.S., Levine, J.S. (1996) Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming. In *J Exp Med*, Volume 184 2231-41.
285. Muller Kobold, A.C., Kallenberg, C.G., Tervaert, J.W. (1999) Monocyte activation in patients with Wegener's granulomatosis. In *Ann Rheum Dis*, Volume 58 237-45.
286. Ohlsson, S. (2005) unpublished data.

287. Zhou, Z., Richard, C., Menard, H.A. (2000) De novo synthesis of proteinase 3 by cytokine primed circulating human polymorphonuclear neutrophils and mononuclear cells. In *J Rheumatol*, Volume 27 2406-11.
288. Just, J., Moog-Lutz, C., Houzel-Charavel, A., Canteloup, S., Grimfeld, A., Witko-Sarsat, V., Cayre, Y.E. (1999) Proteinase 3 mRNA expression is induced in monocytes but not in neutrophils of patients with cystic fibrosis. In *FEBS Lett*, Volume 457 437-40.
289. Yang, J.J., Pendergraft, W.F., Alcorta, D.A., Nachman, P.H., Hogan, S.L., Thomas, R.P., Sullivan, P., Jennette, J.C., Falk, R.J., Preston, G.A. (2004) Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. In *J Am Soc Nephrol*, Volume 15 2103-14.
290. Hastings, J.W. (1983) Biological diversity, chemical mechanisms, and the evolutionary origins of bioluminescent systems. In *J Mol Evol*, Volume 19 309-21.
291. Bronstein, I., Fortin, J., Stanley, P.E., Stewart, G.S., Kricka, L.J. (1994) Chemiluminescent and bioluminescent reporter gene assays. In *Anal Biochem*, Volume 219 169-81.
292. Smith, C.L., Hager, G.L. (1997) Transcriptional regulation of mammalian genes in vivo. A tale of two templates. In *J Biol Chem*, Volume 272 27493-6.
293. McPherson MJ, M.S. (2000) PCR, The Basics: from background to bench. BIOS Scientific Publishers.
294. Ginzinger, D.G. (2002) Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. In *Exp Hematol*, Volume 30 503-12.
295. Kerr, L.D. (1995) Electrophoretic mobility shift assay. In *Methods Enzymol*, Volume 254 619-32.
296. Boyd, K.E., Farnham, P.J. (1999) Coexamination of site-specific transcription factor binding and promoter activity in living cells. In *Mol Cell Biol*, Volume 19 8393-9.
297. Kuo, M.H., Allis, C.D. (1999) In vivo cross-linking and immunoprecipitation for studying dynamic Protein:DNA associations in a chromatin environment. In *Methods*, Volume 19 425-33.
298. Lennartsson, A. (2005) unpublished data.
299. Matys, V., Fricke, E., Geffers, R., Gossling, E., Haubrock, M., Hehl, R., Hornischer, K., Karas, D., Kel, A.E., Kel-Margoulis, O.V., Kloos, D.U., Land, S., Lewicki-Potapov, B., Michael, H., Munch, R., Reuter, I., Rotert, S., Saxel, H., Scheer, M., Thiele, S., Wingender, E. (2003) TRANSFAC: transcriptional regulation, from patterns to profiles. In *Nucleic Acids Res*, Volume 31 374-8.
300. Wasserman, W.W., Sandelin, A. (2004) Applied bioinformatics for the identification of regulatory elements. In *Nat Rev Genet*, Volume 5 276-87.
301. Sandelin, A., Wasserman, W.W., Lenhard, B. (2004) ConSite: web-based prediction of regulatory elements using cross-species comparison. In *Nucleic Acids Res*, Volume 32 W249-52.

302. Cowland, J.B., Borregaard, N. (1999) The individual regulation of granule protein mRNA levels during neutrophil maturation explains the heterogeneity of neutrophil granules. In *J Leukoc Biol*, Volume 66 989-95.
303. Garwicz, D., Lennartsson, A., Jacobsen, S.E., Gullberg, U., Lindmark, A. (2005) Biosynthetic profiles of neutrophil serine proteases in a human bone marrow-derived cellular myeloid differentiation model. In *Haematologica*, Volume 90 38-44.
304. Khanna-Gupta, A., Zibello, T., Sun, H., Lekstrom-Himes, J., Berliner, N. (2001) C/EBP epsilon mediates myeloid differentiation and is regulated by the CCAAT displacement protein (CDP/cut). In *Proc Natl Acad Sci U S A*, Volume 98 8000-5.
305. Marecki, J.C., Cota-Gomez, A., Vaitaitis, G.M., Honda, J.R., Porntadavity, S., St Clair, D.K., Flores, S.C. (2004) HIV-1 Tat regulates the SOD2 basal promoter by altering Sp1/Sp3 binding activity. In *Free Radic Biol Med*, Volume 37 869-80.
306. Xue, L., Wu, J., Zheng, W., Wang, P., Li, J., Zhang, Z., Tong, T. (2004) Sp1 is involved in the transcriptional activation of p16(INK4) by p21(Waf1) in HeLa cells. In *FEBS Lett*, Volume 564 199-204.
307. Dennig, J., Beato, M., Suske, G. (1996) An inhibitor domain in Sp3 regulates its glutamine-rich activation domains. In *Embo J*, Volume 15 5659-67.
308. Capodici, C., Weiss, J. (1996) Both N- and C-terminal regions of the bioactive N-terminal fragment of the neutrophil granule bactericidal/permeability-increasing protein are required for stability and function. In *J Immunol*, Volume 156 4789-96.
309. Horwitz, A.H., Leigh, S.D., Abrahamson, S., Gazzano-Santoro, H., Liu, P.S., Williams, R.E., Carroll, S.F., Theofan, G. (1996) Expression and characterization of cysteine-modified variants of an amino-terminal fragment of bactericidal/permeability-increasing protein. In *Protein Expr Purif*, Volume 8 28-40.
310. Beamer, L.J., Carroll, S.F., Eisenberg, D. (1999) The three-dimensional structure of human bactericidal/permeability-increasing protein: implications for understanding protein-lipopolysaccharide interactions. In *Biochem Pharmacol*, Volume 57 225-9.
311. Ooi, C.E., Weiss, J., Doerfler, M.E., Elsbach, P. (1991) Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/permeability-increasing protein of human neutrophils. In *J Exp Med*, Volume 174 649-55.
312. Ooi, C.E., Weiss, J., Elsbach, P., Frangione, B., Mannion, B. (1987) A 25-kDa NH2-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability-increasing protein. In *J Biol Chem*, Volume 262 14891-4.
313. Gazzano-Santoro, H., Parent, J.B., Grinna, L., Horwitz, A., Parsons, T., Theofan, G., Elsbach, P., Weiss, J., Conlon, P.J. (1992) High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. In *Infect Immun*, Volume 60 4754-61.

314. Weiss, J., Beckerdite-Quagliata, S., Elsbach, P. (1980) Resistance of gram-negative bacteria to purified bactericidal leukocyte proteins: relation to binding and bacterial lipopolysaccharide structure. In *J Clin Invest*, Volume 65 619-28.
315. Weiss, J., Hutzler, M., Kao, L. (1986) Environmental modulation of lipopolysaccharide chain length alters the sensitivity of Escherichia coli to the neutrophil bactericidal/permeability-increasing protein. In *Infect Immun*, Volume 51 594-9.
316. Zaballos, A., Villares, R., Albar, J.P., Martinez, A.C., Marquez, G. (2004) Identification on mouse chromosome 8 of new beta-defensin genes with regionally specific expression in the male reproductive organ. In *J Biol Chem*, Volume 279 12421-6.
317. Orgebin-Crist, M.C. (1967) Sperm maturation in rabbit epididymis. In *Nature*, Volume 216 816-8.
318. von Horsten, H.H., Derr, P., Kirchhoff, C. (2002) Novel antimicrobial peptide of human epididymal duct origin. In *Biol Reprod*, Volume 67 804-13.
319. Li, P., Chan, H.C., He, B., So, S.C., Chung, Y.W., Shang, Q., Zhang, Y.D., Zhang, Y.L. (2001) An antimicrobial peptide gene found in the male reproductive system of rats. In *Science*, Volume 291 1783-5.
320. Zhou, C.X., Zhang, Y.L., Xiao, L., Zheng, M., Leung, K.M., Chan, M.Y., Lo, P.S., Tsang, L.L., Wong, H.Y., Ho, L.S., Chung, Y.W., Chan, H.C. (2004) An epididymis-specific beta-defensin is important for the initiation of sperm maturation. In *Nat Cell Biol*, Volume 6 458-64.
321. Andersson, E., Sorensen, O.E., Frohm, B., Borregaard, N., Egesten, A., Malm, J. (2002) Isolation of human cationic antimicrobial protein-18 from seminal plasma and its association with prostasomes. In *Hum Reprod*, Volume 17 2529-34.
322. Sorensen, O., Arnljots, K., Cowland, J.B., Bainton, D.F., Borregaard, N. (1997) The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. In *Blood*, Volume 90 2796-803.
323. Malm, J., Sorensen, O., Persson, T., Frohm-Nilsson, M., Johansson, B., Bjartell, A., Lilja, H., Stahle-Backdahl, M., Borregaard, N., Egesten, A. (2000) The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attached to spermatozoa. In *Infect Immun*, Volume 68 4297-302.
324. Hammami-Hamza, S., Doussau, M., Bernard, J., Rogier, E., Duquenne, C., Richard, Y., Lefevre, A., Finaz, C. (2001) Cloning and sequencing of SOB3, a human gene coding for a sperm protein homologous to an antimicrobial protein and potentially involved in zona pellucida binding. In *Mol Hum Reprod*, Volume 7 625-32.
325. Wang, D.G., Fan, J.B., Siao, C.J., Berno, A., Young, P., Sapolsky, R., Ghandour, G., Perkins, N., Winchester, E., Spencer, J., Kruglyak, L., Stein, L., Hsie, L., Topaloglou, T., Hubbell, E., Robinson, E., Mittmann, M., Morris, M.S., Shen, N., Kilburn, D., Rioux, J., Nusbaum, C., Rozen, S., Hudson, T.J., Lipshutz, R., Chee, M., Lander, E.S. (1998) Large-scale

- identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. In *Science*, Volume 280 1077-82.
326. Gencik, M. (2000) Proteinase 3 gene polymorphisms and Wegener's granulomatosis. In *Kidney International*, Volume 58 2473-2477.
 327. Piedrafita, F.J. (1996) An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid Hormone-retinoic Acid response element. In *The Journal of Biological Chemistry*, Volume 271 14412-14420.
 328. Reynolds, W.F. (2002) -463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO-ANCA-associated vasculitis. In *Clinical Immunology*, Volume 103 154-160.
 329. Fiebeler, A., Borgmann, S., Woywodt, A., Haller, H., Haubitz, M. (2004) No association of G-463A myeloperoxidase gene polymorphism with MPO-ANCA-associated vasculitis. In *Nephrol Dial Transplant*, Volume 19 969-71.
 330. Lin, K.M., Austin, G.E. (2002) Functional activity of three distinct myeloperoxidase (MPO) promoters in human myeloid cells. In *Leukemia*, Volume 16 1143-53.